<SEC-DOCUMENT>0001493152-21-018929.txt : 20210806
<SEC-HEADER>0001493152-21-018929.hdr.sgml : 20210806
<ACCEPTANCE-DATETIME>20210806172616
ACCESSION NUMBER:		0001493152-21-018929
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20210806
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20210806
DATE AS OF CHANGE:		20210806

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TRxADE HEALTH, INC
		CENTRAL INDEX KEY:			0001382574
		STANDARD INDUSTRIAL CLASSIFICATION:	WHOLESALE-DRUGS PROPRIETARIES & DRUGGISTS' SUNDRIES [5122]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39199
		FILM NUMBER:		211153936

	BUSINESS ADDRESS:	
		STREET 1:		3840 LAND O' LAKES BOULEVARD
		CITY:			LAND O' LAKES
		STATE:			FL
		ZIP:			34639
		BUSINESS PHONE:		(800) 261 0281

	MAIL ADDRESS:	
		STREET 1:		3840 LAND O' LAKES BOULEVARD
		CITY:			LAND O' LAKES
		STATE:			FL
		ZIP:			34639

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	TRXADE GROUP, INC.
		DATE OF NAME CHANGE:	20140207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCELLINK INTERNATIONAL INC.
		DATE OF NAME CHANGE:	20081230

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Bluebird Exploration Co.
		DATE OF NAME CHANGE:	20061204
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:MEDS="http://trxadehealth.com/20210806">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_039_MEDS_trxadehealth.com_20210806 -->
<!-- Field: Set; Name: xdx; ID: xdx_048_20210806_20210806 -->
<!-- Field: Set; Name: xdx; ID: xdx_05F_edei%2D%2DEntityCentralIndexKey_0001382574 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityCentralIndexKey">0001382574</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="meds-20210806.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2021-08-06to2021-08-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001382574</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2021-08-06</xbrli:startDate>
        <xbrli:endDate>2021-08-06</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>&#160;</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>UNITED
STATES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>SECURITIES
AND EXCHANGE COMMISSION</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 12pt Times New Roman, Times, Serif"><b>Washington,
D.C. 20549</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b>FORM
<span id="xdx_90B_edei--DocumentType_c20210806__20210806_zxWJTQnhlhd7"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>CURRENT
REPORT</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>PURSUANT
TO SECTION 13 OR 15(d) OF THE</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SECURITIES
EXCHANGE ACT OF 1934</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Date
of Report (Date of Earliest Event Reported): <span id="xdx_90A_edei--DocumentPeriodEndDate_c20210806__20210806_zRV30m88IQje"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">August 6, 2021</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 18pt Times New Roman, Times, Serif"><b><span id="xdx_909_edei--EntityRegistrantName_c20210806__20210806_z2nBMOTS6Fyj"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityRegistrantName">TRxADE
HEALTH, INC.</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Exact
name of Registrant as specified in its charter)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityIncorporationStateCountryCode_c20210806__20210806_zmkwPoEJ4dud"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_908_edei--EntityFileNumber_c20210806__20210806_z8ZDsqyIz3fc"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityFileNumber">001-39199</ix:nonNumeric></span></b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_901_edei--EntityTaxIdentificationNumber_c20210806__20210806_zzaiyW9TBrij"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityTaxIdentificationNumber">46-3673928</ix:nonNumeric></span></b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State
    or other jurisdiction</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(IRS
    Employer</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">of
    incorporation)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">File
    Number)</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification
    No.)</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_905_edei--EntityAddressAddressLine1_c20210806__20210806_z37MFYkLdU2h"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityAddressAddressLine1">3840
Land O&#8217; Lakes Blvd</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90A_edei--EntityAddressCityOrTown_c20210806__20210806_zmxpfB0E1Kp3"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityAddressCityOrTown">Land
O&#8217; Lakes</ix:nonNumeric></span>, <span id="xdx_906_edei--EntityAddressStateOrProvince_c20210806__20210806_zUXLh7WMpYn4"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt-sec:stateprovnameen" name="dei:EntityAddressStateOrProvince">Florida</ix:nonNumeric></span> <span id="xdx_900_edei--EntityAddressPostalZipCode_c20210806__20210806_zNgEobTXn4g4"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:EntityAddressPostalZipCode">34639</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Address
of principal executive offices) (zip code)</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Registrant&#8217;s
telephone number, including area code: <b><span id="xdx_907_edei--CityAreaCode_c20210806__20210806_znTTpeA9oio7"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:CityAreaCode">800</ix:nonNumeric></span>-<span id="xdx_902_edei--LocalPhoneNumber_c20210806__20210806_zwxNDxONPdoj"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:LocalPhoneNumber">261-0281</ix:nonNumeric></span></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b></b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--WrittenCommunications_c20210806__20210806_zggZxzPqG1Ei"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--SolicitingMaterial_c20210806__20210806_zQwlTkZ436S2"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90E_edei--PreCommencementTenderOffer_c20210806__20210806_zj0Ucxxr8dK5"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_909_edei--PreCommencementIssuerTenderOffer_c20210806__20210806_zHULNIU2o3qe"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Securities
registered pursuant to Section 12(b) of the Act:</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 34%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title
    of each class</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading
    Symbol(s)</b></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 42%; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name
    of each exchange on which registered</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_906_edei--Security12bTitle_c20210806__20210806_zInkNucu3ddi"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:Security12bTitle">Common
                                            Stock,</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">$0001
    Par Value Per Share</span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_905_edei--TradingSymbol_c20210806__20210806_zr4wWjn0RgQ3"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" name="dei:TradingSymbol">MEDS</ix:nonNumeric></span></span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: top"><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90A_edei--SecurityExchangeName_c20210806__20210806_z7H95ajn9xC6"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The
                                            NASDAQ Stock Market LLC</ix:nonNumeric></span></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Nasdaq
    Capital Market)</span></p></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">Emerging
growth company <span id="xdx_908_edei--EntityEmergingGrowthCompany_c20210806__20210806_zUhGo7tXzU1"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleantrue" name="dei:EntityEmergingGrowthCompany">&#9746;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_907_edei--EntityExTransitionPeriod_c20210806__20210806_zgGmYduR6wid"><ix:nonNumeric contextRef="From2021-08-06to2021-08-06" format="ixt:booleanfalse" name="dei:EntityExTransitionPeriod">&#9744;</ix:nonNumeric></span></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>Item 1.01. Entry into a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt"><b></b>At the Market Issuance Sales Agreement</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">On
August 6, 2021, TRxADE HEALTH, INC. (the &#8220;<span style="text-decoration: underline">Company</span>&#8221;) entered into an Equity Distribution Agreement (the &#8220;<span style="text-decoration: underline">Equity
Distribution Agreement</span>&#8221;) with EF Hutton, division of Benchmark Investments, LLC (&#8220;<span style="text-decoration: underline">EF Hutton</span>&#8221;, or the &#8220;<span style="text-decoration: underline">Agent</span>&#8221;).
In accordance with the terms of the Equity Distribution Agreement, the Company may offer and sell from time to time through the Agent
the Company&#8217;s common stock having an aggregate offering price of up to $9,000,000 (the &#8220;<span style="text-decoration: underline">Placement Shares</span>&#8221;).
The Company is currently limited in the number of shares it can sell in the offering due to the offering limitations currently
applicable to the Company under General Instruction I.B.6. of Form S-3 and the Company&#8217;s public float as of the applicable date
of such sales, as well as the number of authorized and unissued shares available for issuance, in accordance with the terms of the Equity
Distribution Agreement.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">Sales
of the Placement Shares under the Equity Distribution Agreement will be made in transactions that are deemed to be &#8220;<span style="text-decoration: underline">at-the-market
offerings</span>&#8221; as defined in Rule 415 under the Securities Act of 1933, as amended (the &#8220;<span style="text-decoration: underline">Securities Act</span>&#8221;), including
sales made by means of ordinary brokers&#8217; transactions, including on The Nasdaq Capital Market, at market prices or as otherwise
agreed to with the Agent. Subject to the terms and conditions of the Equity Distribution Agreement, the Agent will use its reasonable
efforts to sell the Placement Shares from time to time based upon the Company&#8217;s instructions (including any price, time or size
limits or other parameters or conditions the Company may impose). The Company will pay the sales agent a commission of 2.0% of the gross
sales price of any Placement Shares sold under the Equity Distribution Agreement. The Company has also provided the Agent with customary
indemnification rights and has agreed to reimburse the sales agent for certain specified expenses up to $50,000.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">The
Company has no obligation to sell any of the Placement Shares, and may, at any time, suspend the sale of the Placement Shares under the
Equity Distribution Agreement upon proper notice to the other party for any reason and the Agent may also suspend the sale
of Placement Shares at any time. The Equity Distribution Agreement will terminate upon the issuance and sale of all of the Placement
Shares through or to the Agent, unless earlier terminated in accordance with its terms.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The Company intends to use the net proceeds, if any, from the sale
of the Placement Shares pursuant to the Equity Distribution Agreement for general corporate purposes, which may include working capital
or capital expenditures and other investments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif"><span>The
Placement Shares will be issued pursuant to the Company&#8217;s shelf registration statement on Form S-3 (Registration No. 333-248473),
registering the sale of up to $100,000,000 in securities, including common stock, which was declared effective on September 3, 2020.
</span>The Company filed a prospectus supplement, dated August 6, 2021 (the &#8220;<span style="text-decoration: underline">Prospectus Supplement</span>&#8221;), to the prospectus,
dated September 3, 2020, with the Securities and Exchange Commission in connection with the offer and sale of the Placement Shares.</span></p>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">This
Current Report on Form 8-K shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of
these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration
or qualification under the securities laws of any such state or jurisdiction.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif">The
foregoing description of the Equity Distribution Agreement set forth herein does not purport to be complete and is qualified in its entirety
by reference to the full text thereof, a copy of which is filed as <span style="text-decoration: underline">Exhibit 1.1</span> to this Current Report on Form 8-K which is
incorporated herein by reference. The Equity Distribution Agreement has been included to provide investors and security holders with
information regarding its terms. It is not intended to provide any other factual information about the Company or its subsidiaries and
affiliates. The Equity Distribution Agreement contains representations and warranties by the Company made solely for the benefit of the
Agent. The assertions embodied in those representations and warranties are subject to qualifications and limitations agreed to by the
respective parties in negotiating the terms of the Equity Distribution Agreement. Moreover, certain representations and warranties in
the Equity Distribution Agreement were made as of a specified date, may be subject to a contractual standard of materiality different
from what might be viewed as material to investors, or may have been used for the purpose of allocating risk between the Company and
the Agent, rather than establishing matters as facts. Accordingly, the representations and warranties in the Equity Distribution Agreement
should not be relied on by any persons as characterizations of the actual state of facts about the Company at the time they were made
or otherwise. In addition, information concerning the subject matter of the representations and warranties may change after the date
of the Equity Distribution Agreement, which subsequent information may or may not be fully reflected in the Company&#8217;s public
disclosures.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 27pt"><span style="font: 10pt Times New Roman, Times, Serif"></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 2 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
8.01. Other Events.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">As
previously reported in the <a href="https://www.sec.gov/Archives/edgar/data/1382574/000149315221013215/form8-k.htm" style="-sec-extract: exhibit">Current Report on Form 8-K</a> filed by the Company with the Securities and Exchange Commission on May 28, 2021,
on May 27, 2021, the Board of Directors of the Company authorized and approved a share repurchase program for up to $1 million of the
currently outstanding shares of the Company&#8217;s common stock. There was no time frame for the repurchase program, and such program
is to remain in place until a maximum of $1.0 million of the Company&#8217;s common stock has been repurchased or until such program
is discontinued by the Board of Directors. No shares of common stock have been repurchased by the Company pursuant to the share repurchase
program to date.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">On August
5, 2021, in connection with the Company&#8217;s planned entry into the Equity Distribution Agreement with the Agent, the
Board of Directors of the Company elected to pause the share repurchase program during the time period the Equity Distribution
Agreement and the offering described therein, is ongoing.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in; background-color: white"><span style="font: 10pt Times New Roman, Times, Serif">The
legal opinion relating to the Placement Shares is filed as <span style="text-decoration: underline">Exhibit 5.1</span> hereto.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif"><b>Item
9.01. Financial Statements and Exhibits.</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 27pt; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">(d)
Exhibits.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; width: 0.65in"><p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Exhibit</b></span></p>
    <p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>Number</b></span></p></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left"><span style="font: 10pt Times New Roman, Times, Serif"><b>Description
    of the Exhibit</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif">
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">1.1+</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex1-1.htm">Equity Distribution Agreement, dated August 6, 2021 between the Company and EF Hutton, division of Benchmark Investments LLC</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">5.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm">Opinion of The McGeary Law Firm, P.C.</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">23.1*</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top"><span style="font: 10pt Times New Roman, Times, Serif"><a href="ex5-1.htm">Consent of The McGeary Law Firm, P.C. (included in Exhibit 5.1)</a></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: top; text-align: center">104</td>
    <td style="font: 10pt Times New Roman, Times, Serif; vertical-align: bottom">&#160;</td>
    <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; vertical-align: top">Cover Page Interactive Data File
    (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">*
Filed herewith.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">+
Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) of Regulation S-K. A copy of any omitted schedule or exhibit
will be furnished supplementally to the Securities and Exchange Commission upon request; provided, however that the Company may request
confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended, for any schedule or exhibit so furnished.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 3 -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <div style="break-before: page; margin-top: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b>SIGNATURES</b></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font: 10pt Times New Roman, Times, Serif">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td colspan="2" style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><b>TRXADE
    GROUP, INC.</b></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif; width: 50%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 5%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif; width: 45%"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Date:
    August 6, 2021</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">By:</span></td>
    <td style="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif"><i>/s/
    Suren Ajjarapu</i></span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Name:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Suren
    Ajjarapu</span></td></tr>
  <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Title:</span></td>
    <td style="font: 10pt Times New Roman, Times, Serif"><span style="font: 10pt Times New Roman, Times, Serif">Chief
    Executive Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <div style="border-bottom: Black 1.5pt solid; margin-bottom: 6pt"><table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font-size: 10pt"><tr style="vertical-align: top; text-align: left"><td style="width: 100%">&#160;</td></tr></table></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: 10pt Times New Roman, Times, Serif">&#160;</span></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LNpNFN2jQ0WcImOIr8VFKW7NSOt0n+Rf2m2IIRCSe0+uECOxpY0ukeGyylLIsapL5RAyvCGjuaJ3JLt9DH5meNfWsTKuX39gQp5Bz8zGS+XvvbPRFosY5GIi55MoBDmL5RROBxF0ekLmpgs0TqsSlCngxFSzRqe4HT7k6k2GqrZPOiNbTSaGcCwH+QORDCM4UqNexA8LaZqIYNRXILZMz7qLeVpHFaxLrHyWHdB/B1/hIEke -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>ex1-1.htm
<DESCRIPTION>EQUITY DISTRIBUTION AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Exhibit
1.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRxADE
HEALTH, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Up
to $9,000,000 of Shares of Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Equity
Distribution Agreement</U></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
6,</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EF
Hutton, division of Benchmark Investments LLC</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">590
Madison Avenue, 39th Floor</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">New
York, New York 10022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRxADE
HEALTH, INC. , a Delaware corporation (the &ldquo;<B><I>Company</I></B>&rdquo;), proposes to issue and sell through EF Hutton, a division
of Benchmark Investments LLC (the &ldquo;<B><I>Agent</I></B>&rdquo;), as sales agent, up to an aggregate of $9,000,000 of shares of common
stock, par value $0.00001 per share (&ldquo;<B><I>Common Stock</I></B>&rdquo;), of the Company (the &ldquo;<B><I>Shares</I></B>&rdquo;)
on terms set forth herein. The Shares consist entirely of authorized but unissued shares of Common Stock to be issued and sold by the
Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company hereby confirms its agreement with the Agent (this &ldquo;<B><I>Agreement</I></B>&rdquo;) with respect to the sale of the Shares.</FONT></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
<B><I>Representations and Warranties of the Company</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company represents and warrants to, and agrees with, the Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
A registration statement on Form S-3 (No. 333- 248473) (the &ldquo;<I>registration statement</I>&rdquo;) has been filed with the Securities
and Exchange Commission (the &ldquo;<B><I>Commission</I></B>&rdquo;) and was declared effective under the Securities Act of 1933, as
amended (the &ldquo;<B><I>Securities Act of 1933</I></B>&rdquo;), and the rules and regulations promulgated thereunder (the &ldquo;Rules
and Regulations&rdquo; and collectively with the Securities Act of 1933, the &ldquo;<B><I>Securities Act</I></B>&rdquo;)) on September
3, 2020; to the Company&rsquo;s knowledge, no stop order of the Commission preventing or suspending the use of the Base Prospectus (as
defined below), the Prospectus Supplement (as defined below), the Prospectus (as defined below) or any Permitted Free Writing Prospectus
(as defined below), or the effectiveness of the Registration Statement, has been issued, and no proceedings for such purpose have been
instituted or, to the Company&rsquo;s knowledge, are contemplated by the Commission. Except where the context otherwise requires, &ldquo;<B><I>Registration
Statement</I></B>,&rdquo; as used herein, means the registration statement, as amended at the time of such registration statement&rsquo;s
effectiveness for purposes of Section 11 of the Securities Act, as such section applies to the Agent, including (1) all documents filed
as a part thereof or incorporated or deemed to be incorporated by reference therein, (2) any information contained or incorporated by
reference in a prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act, to the extent such information
is deemed, pursuant to Rule 430B or Rule 430C under the Securities Act, to be part of the registration statement at such time, and (3)
any registration statement filed to register the offer and sale of Shares pursuant to Rule 462(b) under the Securities Act (the &ldquo;<B><I>462(b)
Registration Statement</I></B>&rdquo;). Except where the context otherwise requires, &ldquo;<B><I>Base Prospectus</I></B>,&rdquo; as
used herein, means the base prospectus filed as part of the Registration Statement, together with any amendments or supplements thereto
as of the date of this Agreement. Except where the context otherwise requires, &ldquo;<B><I>Prospectus Supplement</I></B>,&rdquo; as
used herein, means the most recent prospectus relating to the Shares, filed or to be filed by the Company with the Commission as part
of the Base Prospectus pursuant to Rule 424(b) under the Securities Act and in accordance with the terms of this Agreement. Except where
the context otherwise requires, &ldquo;<B><I>Prospectus</I></B>,&rdquo; as used herein, means the Prospectus Supplement together with
the Base Prospectus attached to or used with the Prospectus Supplement, as may be amended or supplemented from time to time. &ldquo;<B><I>Permitted
Free Writing Prospectus</I></B>,&rdquo; as used herein, means the documents, if any, listed on <U>Schedule A</U> attached hereto and,
after the date hereof, any &ldquo;issuer free writing prospectus&rdquo; as defined in Rule 433 of the Securities Act, that is expressly
agreed to by the Company and the Agent in writing to be a Permitted Free Writing Prospectus. Any reference herein to the Registration
Statement, the Base Prospectus, the Prospectus Supplement, the Prospectus or any Permitted Free Writing Prospectus shall be deemed to
refer to and include the documents, if any, incorporated by reference, or deemed to be incorporated by reference, therein pursuant to
Item 12 of Form S-3 (the &ldquo;<B><I>Incorporated Documents</I></B>&rdquo;), including, unless the context otherwise requires, the documents,
if any, filed as exhibits to such Incorporated Documents. For purposes of this Agreement, all references to the Registration Statement,
the Rule 462(b) Registration Statement, the Base Prospectus, the Prospectus or any amendment or supplement to any of the foregoing shall
be deemed to include the copy filed with the Commission pursuant to its Electronic Data Gathering, Analysis and Retrieval System (&ldquo;<B><I>EDGAR</I></B>&rdquo;).
All references in this Agreement to financial statements and schedules and other information which is &ldquo;described,&rdquo; &ldquo;contained,&rdquo;
&ldquo;included&rdquo; or &ldquo;stated&rdquo; in the Registration Statement, the Base Prospectus, the Prospectus or any Permitted Free
Writing Prospectus (or other references of like import) shall be deemed to mean and include all such financial statements and schedules
and other information which is incorporated by reference in or otherwise deemed by the Rules and Regulations to be a part of or included
in the Registration Statement, the Base Prospectus, the Prospectus or Permitted Free Writing Prospectus as the case may be. Any reference
herein to the terms &ldquo;<B><I>amend</I></B>,&rdquo; &ldquo;<B><I>amendment</I></B>&rdquo; or &ldquo;<B><I>supplement</I></B>&rdquo;
with respect to the Registration Statement, any Base Prospectus, the Prospectus, the Prospectus Supplement or any Permitted Free Writing
Prospectus shall be deemed to refer to and include the filing of any document under the Securities Exchange Act of 1934, as amended,
and the rules and regulations thereunder (collectively, the &ldquo;<B><I>Exchange Act</I></B>&rdquo;) on or after the initial effective
date of the Registration Statement, or the date of such Base Prospectus, the Prospectus, the Prospectus Supplement or such Permitted
Free Writing Prospectus, if any, as the case may be, and incorporated or deemed to be incorporated therein by reference pursuant to Item
12 of Form S-3. &ldquo;<B><I>Time of Sale</I></B>&rdquo; means each time a Share is purchased pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
(A) The Registration Statement complied or will comply, when it became or becomes effective, and will comply upon the effectiveness of
any amendment thereto and at each Time of Sale and each Settlement Date (as applicable), in all material respects, with the requirements
of the Securities Act; at all times during which a prospectus is required by the Securities Act to be delivered (whether physically or
through compliance with Rule 172 under the Securities Act or any similar rule) in connection with any sale of Shares (the &ldquo;<B><I>Prospectus
Delivery Period</I></B>&rdquo;), the Registration Statement, as may be amended, will comply, in all material respects, with the requirements
of the Securities Act; the conditions to the use of Form S-3 in connection with the offering and sale of the Shares as contemplated hereby
(the &ldquo;<B><I>Offering</I></B>&rdquo;) have been satisfied, subject to the limitations required by General Instruction I.B.6 of Form
S-3; the Registration Statement meets, and the Offering complies with, the requirements of Rule 415 under the Securities Act (including,
without limitation, Rule 415(a)(5)); the Registration Statement did not or will not, when it became or becomes effective and as of the
date hereof, and will not, as of the effective date of any amendment thereto, at each Time of Sale, if any, and at all times during a
Prospectus Delivery Period, contain an untrue statement of a material fact or omit to state a material fact required to be stated therein
or necessary to make the statements therein not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(B)
The Prospectus, as of the date of the Prospectus Supplement, as of the date hereof (if filed with the Commission on or prior to the date
hereof), at each Settlement Date and Time of Sale (as applicable), and at all times during a Prospectus Delivery Period, complied, complies
or will comply, in all material respects, with the requirements of the Securities Act; and the Prospectus, and each supplement thereto,
as of their respective dates, at each Settlement Date or Time of Sale (as applicable), and at all times during a Prospectus Delivery
Period, did not and will not include an untrue statement of a material fact or omit to state a material fact necessary in order to make
the statements therein, in the light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(C)
Each Permitted Free Writing Prospectus, if any, as of its date and as of each Settlement Date and Time of Sale (as applicable), and at
all times during a Prospectus Delivery Period (when taken together with the Prospectus at such time) will not include an untrue statement
of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 2in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
representations and warranties set forth in subparagraphs (A), (B) and (C) above shall not apply to any statement contained in the Registration
Statement, the Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus in reliance upon and in conformity with information
concerning the Agent that is furnished in writing by or on behalf of the Agent expressly for use in the Registration Statement, the Base
Prospectus, the Prospectus or such Permitted Free Writing Prospectus, if any, it being understood and agreed that only such information
furnished by the Agent as of the date hereof consists of the information described in <U>Section 5(b)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
Prior to the execution of this Agreement, the Company has not, directly or indirectly, offered or sold any Shares by means of any &ldquo;prospectus&rdquo;
(within the meaning of the Securities Act) or used any &ldquo;prospectus&rdquo; (within the meaning of the Securities Act) in connection
with the Offering, in each case other than the Base Prospectus or any Permitted Free Writing Prospectus; the Company has not, directly
or indirectly, prepared, used or referred to any Permitted Free Writing Prospectus except in compliance with Rules 164 and 433 under
the Securities Act; assuming that a Permitted Free Writing Prospectus, if any, is sent or given after the Registration Statement was
filed with the Commission (and after such Permitted Free Writing Prospectus, if any, was, if required pursuant to Rule 433(d) under the
Securities Act, filed with the Commission), the Company will satisfy the provisions of Rule 164 or Rule 433 necessary for the use of
a free writing prospectus (as defined in Rule 405) in connection with the Offering; the conditions set forth in one or more of subclauses
(i) through (iv), inclusive, of Rule 433(b)(1) under the Securities Act are satisfied, and the registration statement relating to the
Offering, as initially filed with the Commission or as to be filed with the Commission, includes or will include a prospectus that, other
than by reason of Rule 433 or Rule 431 under the Securities Act, satisfies the requirements of Section 10 of the Securities Act; neither
the Company nor the Agent is disqualified, by reason of subsection (f) or (g) of Rule 164 under the Securities Act, from using, in connection
with the Offering, &ldquo;free writing prospectuses&rdquo; (as defined in Rule 405 under the Securities Act) pursuant to Rules 164 and
433 under the Securities Act; the Company is not an &ldquo;ineligible issuer&rdquo; (as defined in Rule 405 under the Securities Act)
as of the eligibility determination date for purposes of Rules 164 and 433 under the Securities Act with respect to the offering of the
Shares contemplated by the Registration Statement; the parties hereto agree and understand that the content of any and all &ldquo;road
shows&rdquo; (as defined in Rule 433 under the Securities Act) related to the Offering is solely the property of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Each Permitted Free Writing Prospectus, as of its issue date, each Time of Sale and each Settlement Date occurring after such issue date
and at all subsequent times through the Prospectus Delivery Period (as defined below) or until any earlier date that the Company notified
or notifies the Agent as described in <U>Section 3(c)(iii)</U>, did not, does not and will not include any information that conflicted,
conflicts or will conflict with the information contained in the Registration Statement, any Base Prospectus or the Prospectus. The foregoing
sentence does not apply to statements in or omissions from any Permitted Free Writing Prospectus based upon and in conformity with written
information furnished to the Company by the Agent specifically for use therein, it being understood and agreed that the only such information
furnished by the Agent as of the date hereof consists of the information described in <U>Section 5(b)(ii)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The financial statements, including the notes thereto, and the supporting schedules incorporated by reference in the Registration Statement
and the Prospectus comply in all material respects with the requirements of the Securities Act, the Exchange Act and the Rules and Regulations,
and present fairly the financial position as of the dates indicated and the cash flows and results of operations for the periods specified
of the Company. Except as otherwise stated in the Registration Statement and the Prospectus, said financial statements have been prepared
in conformity with United States generally accepted accounting principles (&ldquo;<B><I>GAAP</I></B>&rdquo;) applied on a consistent
basis throughout the periods involved, except in the case of unaudited financials which are subject to normal year-end adjustments and
do not contain certain footnotes. No other financial statements or supporting schedules are required to be included or incorporated by
reference in the Registration Statement or the Prospectus. The other financial information included in the Registration Statement and
the Prospectus present fairly the information included therein and have been prepared on a basis consistent with that of the financial
statements that are included in the Registration Statement and the Prospectus and the books and records of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The Company has been duly incorporated and validly exists as a corporation in good standing under the laws of the State of Delaware.
The Company has all requisite corporate power and authority to carry on its business as it is currently being conducted and as described
in the Registration Statement and the Prospectus, and to own, lease and operate its properties. The Company is duly qualified to do business
and is in good standing as a foreign corporation in each jurisdiction in which the character or location of its properties (owned, leased
or licensed) or the nature or conduct of its business makes such qualification necessary, except, in each case, for those failures to
be so qualified or in good standing which (individually and in the aggregate) would not reasonably be expected to have a Material Adverse
Effect (as defined below).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
All of the issued shares of capital stock of the Company have been duly authorized and validly issued and are fully paid and nonassessable,
have been issued in compliance with all applicable federal and state securities laws and none of those shares was issued in violation
of any preemptive rights, rights of first refusal or other similar rights to the extent any such rights were not waived; the Shares have
been duly authorized and, when issued and delivered against payment therefor as provided in this Agreement, will be validly issued, fully
paid and non-assessable, and the issuance of the Shares is not subject to any preemptive rights, rights of first refusal or other similar
rights that have not heretofore been waived (with copies of such waivers provided or made available to the Agent). The Shares conform
in all material respects to the descriptions thereof contained in the Registration Statement and the Prospectus under the heading &ldquo;Description
of Capital Stock.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
MaloneBailey LLP (the &ldquo;<B><I>Auditor</I></B>&rdquo;), whose reports relating to the Company is incorporated by reference into the
Registration Statement and the Prospectus, is an independent registered public accounting firm as required by the Securities Act, the
Exchange Act and the Rules and Regulations and the Public Company Accounting Oversight Board (the &ldquo;<B><I>PCAOB</I></B>&rdquo;).
To the Company&rsquo;s knowledge, the Auditor is not in violation of the auditor independence requirements of the Sarbanes-Oxley Act
of 2002 (&ldquo;<B><I>Sarbanes-Oxley</I></B>&rdquo;) as such requirements pertain to the Auditor&rsquo;s relationship with the Company.
Except as disclosed in the Registration Statement and the Prospectus, and except for any such non-audit services that were pre-approved
by the Audit Committee of the Company&rsquo;s Board of Directors in accordance with Sections 10A(h) and (i) of the Exchange Act, the
Auditor has not, during the periods covered by the financial statements included in the Registration Statement and the Prospectus, provided
to the Company any non-audit services, as such term is used in Section 10A(g) of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
Subsequent to the respective dates as of which information is presented in the Registration Statement and the Prospectus, and except
as disclosed in the Registration Statement and the Prospectus: (i) the Company has not declared, paid or made any dividends or other
distributions of any kind on or in respect of its capital stock, and (ii) there has been no material adverse change or, to the Company&rsquo;s
knowledge, any development which could reasonably be expected to result in a material adverse change in the future, whether or not arising
from transactions in the ordinary course of business, in or affecting: (A) the business, condition (financial or otherwise), results
of operations, stockholders&rsquo; equity, properties or prospects of the Company; (B) the long-term debt or capital stock of the Company;
or (C) the Offering or consummation of any of the other transactions contemplated by this Agreement, the Registration Statement and the
Prospectus (a &ldquo;<B><I>Material Adverse Effect</I></B>&rdquo;). Since the date of the latest balance sheet included in the Registration
Statement and the Prospectus, the Company has not incurred or undertaken any liabilities or obligations, whether direct or indirect,
liquidated or contingent, matured or unmatured, or entered into any transactions, including any acquisition or disposition of any business
or asset, which are material to the Company, except for liabilities, obligations and transactions which are disclosed in the Registration
Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
The subsidiaries of the Company (the &ldquo;<B><I>Subsidiaries</I></B>&rdquo;), together with their respective jurisdictions of incorporation
are listed on <U>Schedule E</U> hereto. Except as indicated on <U>Schedule E</U> hereto, each of the Subsidiaries is directly or indirectly
wholly-owned by the Company and no person or entity has any right to acquire any equity interest in any of the Subsidiaries Except as
otherwise disclosed in the Registration Statement and the Prospectus, the Company holds no ownership or other interest, nominal or beneficial,
direct or indirect, in any corporation, partnership, joint venture or other business entity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xi)
Neither the Company nor any of its Subsidiaries is: (i) in violation of its certificate of incorporation or bylaws or other organizational
documents, (ii) in default under any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which it
is a party or by which it is bound or to which any of its property or assets is subject; and no event has occurred which, with notice
or lapse of time or both, would constitute a default under or result in the creation or imposition of any lien, security interest, charge
or other encumbrance (a &ldquo;<B><I>Lien</I></B>&rdquo;) upon any of its property or assets pursuant to, any indenture, mortgage, deed
of trust, loan agreement or other agreement or instrument to which it is a party or by which it is bound or to which any of its property
or assets is subject, or (iii) in violation in any respect of any applicable law, rule, regulation, ordinance, directive, judgment, decree
or order of any judicial, regulatory or other legal or governmental agency or body, foreign or domestic, except, in the case of subsections
(ii) and (iii) above, for such violations or defaults which (individually or in the aggregate) would not reasonably be expected to have
a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xii)
The Company has all requisite corporate power and authority to execute and deliver this Agreement and all other agreements, documents,
certificates and instruments required to be delivered pursuant to this Agreement. The Company&rsquo;s execution, delivery and performance
under this Agreement and each of the transactions contemplated hereby have been duly authorized by all necessary corporate action. This
Agreement has been duly and validly executed and delivered by the Company and constitutes the legal, valid and binding obligation of
the Company and is enforceable against the Company in accordance with its terms, except (i) as such enforceability may be limited by
bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally; (ii) as enforceability of any indemnification
or contribution provision may be limited under federal and state securities laws; and (iii) that the remedy of specific performance and
injunctive and other forms of equitable relief may be subject to the equitable defenses and to the discretion of the court before which
any proceeding therefor may be brought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiii)
The execution, delivery and performance of this Agreement and all other agreements, documents, certificates and instruments required
to be delivered pursuant to this Agreement and the consummation of the transactions contemplated hereby do not and will not: (i) conflict
with, require consent under or result in a breach of any of the terms and provisions of, or constitute a default (or an event which with
notice or lapse of time, or both, would constitute a default) under, or result in the creation or imposition of any Lien upon any property
or assets of the Company or any of its Subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement,
instrument, franchise, license or permit to which the Company or any of its Subsidiaries is a party or by which the Company or any of
its Subsidiaries or any of their respective properties, operations or assets may be bound, (ii) violate or conflict with any provision
of the certificate of incorporation, bylaws or other organizational documents of the Company or any of its Subsidiaries, (iii) violate
or conflict with any applicable law, rule, regulation, ordinance, directive, judgment, decree or order of any judicial, regulatory or
other legal or governmental agency or body, domestic or foreign, or (iv) trigger a reset or repricing of any outstanding securities of
the Company or any of its Subsidiaries, except in the case of subsections (i) and (iii) for any default, conflict or violation that would
not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xiv)
Except as disclosed in the Registration Statement and the Prospectus, the Company and each of its Subsidiaries has all consents, approvals,
authorizations, orders, registrations, qualifications, licenses, filings, grants, franchises, easements, certificates and permits of,
with and from all judicial, regulatory and other legal or governmental agencies, self-regulatory agencies, authorities and bodies and
all third parties, foreign and domestic, including, without limitation, the U.S. Food and Drug Administration (&ldquo;<B><I>FDA</I></B>&rdquo;)
or equivalent in non-U.S. jurisdictions (collectively, the &ldquo;<B><I>Consents</I></B>&rdquo;), to own, lease and operate its respective
properties and conduct its respective business as it is now being conducted and as disclosed in the Registration Statement and the Prospectus,
and each such Consent is valid and in full force and effect, except which (individually or in the aggregate), in each such case, would
not reasonably be expected to have a Material Adverse Effect. Neither the Company nor any of its Subsidiaries has received notice of
any investigation or proceedings which results in or, if decided adversely to the Company or its Subsidiaries could reasonably be expected
to result in, the revocation of, or imposition of a materially burdensome restriction on, any Consent. No Consent contains a materially
burdensome restriction not adequately disclosed in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xv)
The Company and each of its Subsidiaries is in compliance with all applicable laws, rules, regulations, ordinances, directives, judgments,
decrees and orders, foreign and domestic, except for any non-compliance the consequences of which would not have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvi)
Prior to the Settlement Date, the Shares shall have been approved for listing on the NASDAQ Capital Market, subject to official notice
of issuance (the &ldquo;<B><I>Exchange</I></B>&rdquo;), and the Company has taken no action designed to, or likely to have the effect
of, delisting the Shares nor has the Company received any notification that the Exchange is contemplating terminating such listing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xvii)
No consent of, with or from any judicial, regulatory or other legal or governmental agency or body or any third party, foreign or domestic
is required for the execution, delivery and performance of this Agreement or consummation of each of the transactions contemplated by
this Agreement, including the issuance, sale and delivery of the Shares to be issued, sold and delivered hereunder, except (i) such as
may have previously been obtained (with copies of such consents provided to the Agent), each of which is in full force and effect as
of the date hereof, (ii) the registration under the Securities Act of the Shares, which has become effective and which remains in full
force and effect as of the date hereof, (iii) such consents as may be required under state securities or blue sky laws or the bylaws
and rules of the Exchange, and (iv) the Financial Industry Regulatory Authority, Inc. (&ldquo;<B><I>FINRA</I></B>&rdquo;) in connection
with the purchase and distribution of the Shares by the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xviii)
Except as disclosed in the Registration Statement and the Prospectus, there is no judicial, regulatory, arbitral or other legal or governmental
proceeding, inquiry, investigation or other suit, litigation or arbitration, domestic or foreign, pending to which the Company or any
of its Subsidiaries is a party or of which any of their respective properties, operations or assets is the subject which (i) individually
or in the aggregate, if determined adversely to the Company or any such Subsidiaries would reasonably be expected to have a Material
Adverse Effect, or (ii) is reasonably likely to materially and adversely affect the consummation of the transactions contemplated in
this Agreement or the performance by the Company of its obligations hereunder. To the Company&rsquo;s knowledge, no such proceeding,
litigation or arbitration is threatened or contemplated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xix)
There are no pro forma or as adjusted financial statements which are required to be included in the Registration Statement and the Prospectus
in accordance with Regulation S-X which have not been included as so required. The pro forma and pro forma as adjusted financial information
included in the Registration Statement and the Prospectus have been properly compiled and prepared in accordance with the applicable
requirements of the Securities Act and the Rules and Regulations and include all adjustments necessary to present fairly in accordance
with GAAP the pro forma and as adjusted financial position of the Company presented therein at the respective dates indicated and its
cash flows and the results of operations for the respective periods specified. The assumptions used in preparing the pro forma and pro
forma as adjusted financial information included in the Registration Statement and the Prospectus provide a reasonable basis for presenting
the significant effects directly attributable to the transactions or events described therein. The related pro forma and pro forma as
adjusted adjustments give appropriate effect to those assumptions; and the pro forma and pro forma as adjusted financial information
reflect the proper application of those adjustments to the corresponding historical financial statement amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)
The statistical, industry-related and market-related data included in the Registration Statement and the Prospectus are based on or derived
from sources which the Company reasonably and in good faith believes are reliable and accurate, and the Company has obtained the written
consent to the use of such data from such sources, to the extent required, except for such failures to obtain written consent which (individually
and in the aggregate) would not reasonably be expected to have a Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxi)
The Company and each of its Subsidiaries has established and maintains disclosure controls and procedures over financial reporting (as
defined in Rules 13a-15 and 15d-15 under the Exchange Act) and such controls and procedures are designed to ensure that information relating
to the Company and its Subsidiaries required to be disclosed in the reports that the Company files or submits under the Exchange Act
is accumulated and communicated to the Company&rsquo;s management, including its principal executive and principal financial officers,
or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. The Company has utilized
such controls and procedures in preparing and evaluating the disclosures in the Registration Statement and in the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxii)
Except as disclosed in the Registration Statement and the Prospectus, neither the board of directors nor the audit committee has been
informed, nor is the Company aware, of: (i) any significant deficiencies or material weaknesses in the design or operation of internal
control over financial reporting which are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize
and report financial information; or (ii) any fraud, whether or not material, that involves management or other employees who have a
significant role in the Company&rsquo;s internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiii)
Neither the Company nor any of its Subsidiaries has taken, directly or indirectly, any action which constitutes or is designed to cause
or result in, or which could reasonably be expected to constitute, cause or result in, the stabilization or manipulation of the price
of any security to facilitate the sale or resale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxiv)
Neither the Company nor any of its Subsidiaries or Affiliates (within the meaning of the Securities Act) has, prior to the date hereof,
made any offer or sale of any securities which are required to be &ldquo;integrated&rdquo; pursuant to the Securities Act or the Rules
and Regulations with the offer and sale of the Shares pursuant to the Registration Statement. Except as disclosed in the Registration
Statement and the Prospectus, neither the Company nor any of its Subsidiaries or Affiliates has sold or issued any securities during
the six-month period preceding the date of the Prospectus, including but not limited to any sales pursuant to Rule 144A, Regulation D
or Regulation S under the Securities Act, other than shares of Common Stock issued pursuant to equity incentive plans, employee stock
purchase plans, employee benefit plans, qualified stock option plans or employee compensation plans or pursuant to outstanding options,
convertible notes, rights or warrants to purchase shares of Common Stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxv)
To the knowledge of the Company, the biographies of the Company&rsquo;s officers and directors incorporated into the Registration Statement
are true and correct in all material respects and the Company has not become aware of any information which would cause the information
disclosed in the questionnaires previously completed by the directors and officers of the Company to become inaccurate and incorrect
in any material respect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvi)
To the knowledge of the Company, no director or officer of the Company or any of its Subsidiaries is subject to any non-competition agreement
or non-solicitation agreement with any employer or prior employer which could materially affect his or her ability to be and act in his
or her respective capacity of the Company or its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxvii)
The Company is not and, at all times up to and including the consummation of the transactions contemplated by this Agreement, and after
giving effect to application of the Net Proceeds (as defined below), will not be, subject to registration as an &ldquo;investment company&rdquo;
under the Investment Company Act of 1940, as amended, and is not and will not be an entity &ldquo;controlled&rdquo; by an &ldquo;investment
company&rdquo; within the meaning of such act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxviii)
No relationship, direct or indirect, exists between or among any of the Company or, to the Company&rsquo;s knowledge, any Affiliate of
the Company, on the one hand, and any director, officer, stockholder, customer or supplier of the Company or, to the Company&rsquo;s
knowledge, any Affiliate of the Company, on the other hand, which is required by the Securities Act, the Exchange Act or the Rules and
Regulations to be described in the Registration Statement or the Prospectus which is not so described as required. There are no outstanding
loans, advances (except normal advances for business expenses in the ordinary course of business) or guarantees of indebtedness by the
Company or any of its Subsidiaries to or for the benefit of any of the officers or directors of the Company or any of their respective
family members, except as described in the Registration Statement and the Prospectus. The Company has not, in violation of Sarbanes-Oxley,
directly or indirectly extended or maintained credit, arranged for the extension of credit, or renewed an extension of credit, in the
form of a personal loan to or for any director or executive officer of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxix)
The Company is in compliance with the rules and regulations promulgated by The NASDAQ Stock Market LLC or any other governmental or self-regulatory
entity or agency having jurisdiction over the Company, except for such failures to be in compliance which (individually and in the aggregate)
would not reasonably be expected to have a Material Adverse Effect. Without limiting the generality of the foregoing: (i) all members
of the Company&rsquo;s board of directors who are required to be &ldquo;independent&rdquo; (as that term is defined under the rules of
The NASDAQ Stock Market LLC), including, without limitation, all members of the audit committee of the Company&rsquo;s board of directors,
meet the qualifications of independence as set forth under applicable laws, rules and regulations and (ii) the audit committee of the
Company&rsquo;s board of directors has at least one member who is an &ldquo;audit committee financial expert&rdquo; (as that term is
defined under applicable laws, rules and regulations).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxx)
The Company and each of its Subsidiaries owns or leases all such properties (other than intellectual property, which is covered below)
as are necessary to the conduct of its business as presently operated and as described in the Registration Statement and the Prospectus.
The Company and each of its Subsidiaries has good and marketable title in fee simple to all real property and good and marketable title
to all personal property owned by it, in each case free and clear of all Liens except such as are described in the Registration Statement
and the Prospectus or such as would not (individually or in the aggregate) have a Material Adverse Effect. Any real property and buildings
held under lease or sublease by the Company or any of its Subsidiaries are held by it under valid, subsisting and, to the Company&rsquo;s
knowledge, enforceable leases with such exceptions as are not material to, and do not materially interfere with, the use made and proposed
to be made of such property and buildings by the Company or any of its Subsidiaries. Neither the Company nor any of its Subsidiaries
has received any written notice of any claim adverse to its ownership of any real or material personal property or of any claim against
the continued possession of any real property, whether owned or held under lease or sublease by the Company or any of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxi)
The Company and each of its Subsidiaries: (i) owns, possesses or has the right to use all patents, patent applications, trademarks, service
marks, trade names, trademark registrations, service mark registrations, copyrights, licenses, formulae, customer lists and know-how
and other intellectual property (including trade secrets and other unpatented and/or unpatentable proprietary or confidential information,
systems or procedures, &ldquo;<B><I>Intellectual Property</I></B>&rdquo;) necessary for the conduct of its businesses as being conducted
and as described in the Registration Statement and the Prospectus, except as disclosed in the Registration Statement or the Prospectus,
and (ii) the Company has no knowledge that the conduct of its business or the business of any of its Subsidiaries conflicts or will conflict
with the rights of others, and neither the Company nor any of its Subsidiaries has received any written notice of any claim of conflict
with, any right of others. To the Company&rsquo;s knowledge, there is no infringement by third parties of any such Intellectual Property,
except which (individually and in the aggregate) would not reasonably be expected to have a Material Adverse Effect; there is no pending
or, to the Company&rsquo;s knowledge, threatened, action, suit, proceeding or claim by others challenging the rights of the Company or
any of its Subsidiaries in or to any such Intellectual Property, and the Company is unaware of any facts which would form a reasonable
basis for any such claim; and there is no pending or, to the Company&rsquo;s knowledge, threatened, action, suit, proceeding or claim
by others that the Company or any of its Subsidiaries infringes or otherwise violates any patent, trademark, copyright, trade secret
or other proprietary rights of others, and the Company is unaware of any other fact which would form a reasonable basis for any such
claim. Except as set forth in the Registration Statement and the Prospectus, neither the Company nor any of its Subsidiaries has received
any claim for royalties or other compensation from any person, including any employee of the Company or any of its Subsidiaries who made
inventive contributions to the technology or products of the Company that are pending or unsettled, and except as set forth in the Registration
Statement and the Prospectus neither the Company nor any of its Subsidiaries has or will have any obligation to pay royalties or other
compensation to any person on account of inventive contributions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxii)
The agreements and documents described in the Registration Statement and the Prospectus conform in all material respects to the descriptions
thereof contained therein and there are no agreements or other documents required by the applicable provisions of the Securities Act
to be described in the Registration Statement or the Prospectus or to be filed with the Commission as exhibits to the Registration Statement,
that have not been so described or filed. Each agreement or other instrument (however characterized or described) to which the Company
or any of its Subsidiaries is a party or by which its respective properties or business is or may be bound or affected and (i) that is
referred to in the Registration Statement or the Prospectus or attached as an exhibit thereto, or (ii) is material to the business of
the Company or any of its Subsidiaries, has been duly and validly executed by the Company or such Subsidiary, is in full force and effect
in all material respects and is enforceable against the Company or such Subsidiary in accordance with its terms, except (x) as such enforceability
may be limited by bankruptcy, insolvency, reorganization or similar laws affecting creditors&rsquo; rights generally, (y) as enforceability
of any indemnification or contribution provision may be limited under the foreign, federal and state securities laws, and (z) that the
remedy of specific performance and injunctive and other forms of equitable relief may be subject to the equitable defenses and to the
discretion of the court before which any proceeding therefor may be brought, and none of such agreements or instruments has been assigned
by the Company or any of its Subsidiaries, and neither the Company nor any of its Subsidiaries nor, to the Company&rsquo;s knowledge,
any other party is in breach or default thereunder and, to the Company&rsquo;s knowledge, no event has occurred that, with the lapse
of time or the giving of notice, or both, would constitute a breach or default thereunder, in any such case, which would result in a
Material Adverse Effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiii)
The disclosures in the Registration Statement and the Prospectus concerning the effects of foreign, federal, state and local regulation
on the business of the Company and its Subsidiaries as currently contemplated are correct in all material respects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxiv)
The Company and each of its Subsidiaries has accurately prepared and filed all federal, state, foreign and other tax returns that are
required to be filed by it through the date hereof, or has received timely extensions thereof, and has paid or made provision for the
payment of all material taxes, assessments, governmental or other similar charges, including without limitation, all sales and use taxes
and all taxes which the Company or any of its Subsidiaries is obligated to withhold from amounts owing to employees, creditors and third
parties, with respect to the periods covered by such tax returns, whether or not such amounts are shown as due on any tax return (except
as currently being contested in good faith and for which reserves required by GAAP have been created in the financial statements of the
Company). No deficiency assessment with respect to a proposed adjustment of the federal, state, local or foreign taxes of the Company
or any of its Subsidiaries is pending or, to the Company&rsquo;s knowledge, threatened. The accruals and reserves on the books and records
of the Company in respect of tax liabilities for any taxable period not finally determined are adequate to meet any assessments and related
liabilities for any such period and, since the date of the Company&rsquo;s most recent audited financial statements, the Company has
not incurred any material liability for taxes other than in the ordinary course of its business. There is no tax lien, whether imposed
by any federal, state, foreign or other taxing authority, outstanding against the assets, properties or business of the Company or any
of its Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxv)
No labor disturbance or dispute by or with the employees of the Company or any of its Subsidiaries which, individually or in the aggregate,
would reasonably be expected to have a Material Adverse Effect, currently exists or, to the Company&rsquo;s knowledge, is threatened.
The Company and each of its Subsidiaries is in compliance in all material respects with the labor and employment laws and collective
bargaining agreements and extension orders applicable to its employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvi)
Except as would not be reasonably expected, individually or in the aggregate, to have a Material Adverse Effect, the Company and each
of its Subsidiaries is in compliance with all Environmental Laws (as hereinafter defined), and, to the Company&rsquo;s knowledge, no
future material expenditures are or will be required in order to comply therewith. Neither the Company nor any of its Subsidiaries has
received any written notice or communication that relates to or alleges any actual or potential violation or failure to comply with any
Environmental Laws that would, individually or in the aggregate, be reasonably expected to have a Material Adverse Effect. As used herein,
the term &ldquo;<B><I>Environmental Laws</I></B>&rdquo; means all applicable laws and regulations, including any licensing, permits or
reporting requirements, and any action by a federal, state or local government entity, pertaining to the protection of the environment,
protection of public health, protection of worker health and safety, or the handling of hazardous materials, including without limitation,
the Clean Air Act, 42 U.S.C. &sect; 7401, et seq., the Comprehensive Environmental Response, Compensation and Liability Act of 1980,
42 U.S.C. &sect; 9601, et seq., the Federal Water Pollution Control Act, 33 U.S.C. &sect; 1321, et seq., the Hazardous Materials Transportation
Act, 49 U.S.C. &sect; 1801, et seq., the Resource Conservation and Recovery Act, 42 U.S.C. &sect; 690-1, et seq., and the Toxic Substances
Control Act, 15 U.S.C. &sect; 2601, et seq.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxvii)
As to each product or product candidate subject to the jurisdiction of the U.S. Food and Drug Administration FDA under the Federal Food,
Drug and Cosmetic Act, as amended, and the regulations thereunder (&ldquo;<B><I>FDCA</I></B>&rdquo;) and/or the jurisdiction of the non-U.S.
counterparts thereof that is currently being tested by the Company or any of its Subsidiaries (each such product, a &ldquo;<B><I>Product</I></B>&rdquo;),
such Product is being tested by the Company or such Subsidiary in compliance with all applicable requirements under FDCA and/or and similar
laws, rules and regulations relating to registration, investigational use, premarket clearance, licensure, or application approval, good
manufacturing practices, good laboratory practices, good clinical practices, product listing, quotas, advertising, record keeping and
filing of reports, except where the failure to be in compliance would not have a Material Adverse Effect. Except as disclosed in the
Registration Statement and the Prospectus, the Company and each of its Subsidiaries currently has no products that have been approved
by the FDA or any non-U.S. counterparts thereof to be manufactured, packaged, labeled, distributed, sold and/or marketed. Except as disclosed
in the Registration Statement or the Prospectus, there is no pending, completed or, to the Company&rsquo;s knowledge, threatened, action
(including any lawsuit, arbitration, or legal or administrative or regulatory proceeding, charge, complaint, or investigation) against
the Company or any of its Subsidiaries and the neither Company nor any of its Subsidiaries has received any written notice, warning letter
or other communication from the FDA or any other governmental entity or any non-U.S. counterparts thereof, in either case which (i) contests
the premarket clearance, licensure, registration or approval of, the uses of, the distribution of, the manufacturing or packaging of,
the testing of, the sale of, or the labeling and promotion of any Product, (ii) imposes a clinical hold on any clinical investigation
by the Company or any of its Subsidiaries, (iii) enters or proposes to enter into a consent decree of permanent injunction with the Company
or any of its Subsidiaries, or (iv) otherwise alleges any violation of any laws, rules or regulations by the Company or any of its Subsidiaries,
and which, either individually or in the aggregate, would have a Material Adverse Effect. The properties, business and operations of
the Company and each of its Subsidiaries have been and are being conducted in all material respects in accordance with all applicable
laws, rules and regulations of the FDA and non-U.S. counterparts thereof. Neither the Company nor any of its Subsidiaries has been informed
by the FDA or any non-U.S. counterparts thereof that such agency will prohibit the marketing, sale, license or use of any Product nor
has the FDA or a non-U.S. counterpart thereof provided any written notice that could reasonably be expected to preclude the approval
or the clearing for marketing of any Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxviii)
The clinical, pre-clinical and other studies and tests (&ldquo;<B><I>Studies</I></B>&rdquo;) conducted by or on behalf of or sponsored
by the Company or any of its Subsidiaries that are described or referred to in the Registration Statement and the Prospectus were and,
if still pending, are, being conducted in accordance with all applicable statutes, laws, rules and regulations (including, without limitation,
those administered by the FDA or by any foreign, federal, state or local governmental or regulatory authority performing functions similar
to those performed by the FDA), as well as the protocols, procedures and controls designed and approved for such Studies and with standard
medical and scientific research procedures, except where the failure to be so conducted would not have a Material Adverse Effect. The
descriptions of the results of such Studies that are described or referred to in the Registration Statement and the Prospectus are accurate
and complete in all material respects and fairly present the data derived from such Studies. Except as disclosed in the Registration
Statement and the Prospectus, neither the Company nor any of its Subsidiaries has received any written notices or other correspondence
from the FDA or any other foreign, federal, state or local governmental or regulatory authority performing functions similar to those
performed by the FDA requiring the termination or suspension of such Studies, other than ordinary course communications with respect
to modifications in connection with the design and implementation of such Studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xxxix)
Except as would not result in a Material Adverse Effect, neither th the Company nor any of its Subsidiaries has failed to file with the
applicable regulatory authorities (including the FDA or any foreign, federal, state or local governmental or regulatory authority performing
functions similar to those performed by the FDA and having jurisdiction over the Company or its Subsidiaries) any filing, declaration,
listing, registration, report or submission that is required to be so filed for the business operation of the Company and its Subsidiaries
as currently conducted. All such filings were in compliance with applicable laws when filed and no deficiencies have been asserted in
writing by any applicable regulatory authority (including, without limitation, the FDA or any foreign, federal, state or local governmental
or regulatory authority performing functions similar to those performed by the FDA) with respect to any such filings, declarations, listings,
registrations, reports or submissions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xl)
The Registration Statement and the Prospectus identify each employment, severance or other similar agreement, arrangement or policy and
each material arrangement providing for insurance coverage, benefits, bonuses, stock options or other forms of incentive compensation,
or post-retirement insurance, compensation or benefits which: (i) is entered into, maintained or contributed to, as the case may be,
by the Company and (ii) covers any officer or director or former officer or former director of the Company, in each case to the extent
required by the Rules and Regulations. These contracts, plans and arrangements are referred to collectively in this Agreement as the
&ldquo;<B><I>Benefit Arrangements</I></B>.&rdquo; Each Benefit Arrangement has been maintained in material compliance with its terms
and with requirements prescribed by any and all statutes, orders, rules and regulations that are applicable to that Benefit Arrangement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xli)
Except as set forth in the Registration Statement or the Prospectus, the Company is not a party to or subject to any employment contract
or arrangement providing for annual future compensation, or the opportunity to earn annual future compensation (whether through fixed
salary, bonus, commission, options or otherwise) of more than $120,000 to any executive officer or director.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlii)
The conditions for use of Form S-3 to register the Offering under the Securities Act, as set forth in the General Instructions to such
Form, have been satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliii)
Except as disclosed in the Registration Statement and the Prospectus, neither the execution of this Agreement nor the consummation of
the Offering, constitutes a triggering event under any Benefit Arrangement or any other employment contract, whether or not legally enforceable,
which (either alone or upon the occurrence of any additional or subsequent event) will or may result in any payment (of severance pay
or otherwise), acceleration, increase in vesting or increase in benefits to any current or former participant, employee or director of
the Company other than an event that is not material to the financial condition or business of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xliv)
Neither the Company nor, to the Company&rsquo;s knowledge, any of its employees or agents or any of the employees or agents of any of
its Subsidiaries, has at any time during the last three (3) years: (i) made any unlawful contribution to any candidate for foreign office,
or failed to disclose fully any contribution in violation of law, or (ii) made any payment to any federal or state governmental officer
or official or other person charged with similar public or quasi-public duties in the United States, other than payments that are not
prohibited by the laws of the United States or any jurisdiction thereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlv)
The Company has not offered, or caused the Agent to offer, any Shares to any person or entity with the intention of unlawfully influencing:
(i) a supplier of the Company or any of its Subsidiaries to alter the supplier&rsquo;s level or type of business with the Company or
any of its Subsidiaries or (ii) a journalist or publication to write or publish favorable information about the Company or any of its
Subsidiaries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvi)
The operations of the Company and each of its Subsidiaries are and have been conducted at all times in compliance in all material respects
with applicable financial record keeping and reporting requirements and money laundering statutes of the United States and, to the Company&rsquo;s
knowledge, all other jurisdictions to which the Company or any of its Subsidiaries is subject, the rules and regulations thereunder and
any related or similar rules, regulations or guidelines, issued, administered or enforced by any applicable governmental agency (collectively,
the &ldquo;<B><I>Money Laundering Laws</I></B>&rdquo;), and no action, suit or proceeding by or before any court or governmental agency,
authority or body or any arbitrator involving the Company or any of its Subsidiaries with respect to the Money Laundering Laws is pending
or, to the Company&rsquo;s knowledge, threatened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlvii)
Neither the Company nor any of its Subsidiaries, nor, to the Company&rsquo;s knowledge, any director, officer, agent, employee or Affiliate
of the Company or any of its Subsidiaries is currently subject to any U.S. sanctions administered by the Office of Foreign Assets Control
of the U.S. Treasury Department (&ldquo;<B><I>OFAC</I></B>&rdquo;); and the Company will not directly or indirectly use the proceeds
of the Offering, or lend, contribute or otherwise make available such proceeds to any joint venture partner or other person or entity,
for the purpose of financing the activities of any person currently subject to any U.S. sanctions administered by OFAC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlviii)
None of the Company, any of its Subsidiaries, any of their respective directors or officers or, to the Company&rsquo;s knowledge, any
agent, employee, affiliate or other person acting on behalf of the Company or any of its Subsidiaries has engaged in any activities sanctionable
under the Comprehensive Iran Sanctions, Accountability, and Divestment Act of 2010, the Iran Sanctions Act of 1996, the National Defense
Authorization Act for Fiscal Year 2012, the Iran Threat Reduction and Syria Human Rights Act of 2012 or any Executive Order relating
to any of the foregoing (collectively, and as each may be amended from time to time, the &ldquo;<B><I>Iran Sanctions</I></B>&rdquo;);
and the Company will not directly or indirectly use the proceeds of the Offering, or lend, contribute or otherwise make available such
proceeds to any subsidiary, joint venture partner or other person or entity, for the purpose of engaging in any activities sanctionable
under the Iran Sanctions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xlix)
Except as described in the Registration Statement and the Prospectus, there are no claims, payments, arrangements, agreements or understandings
relating to the payment of a finder&rsquo;s, consulting or origination fee by the Company or any officer, director or stockholder of
the Company (each, an &ldquo;<B><I>Insider</I></B>&rdquo;) with respect to the sale of the Shares hereunder or any other arrangements,
agreements or understandings of the Company or, to the Company&rsquo;s knowledge, any of its stockholders that may affect the Agent&rsquo;s
compensation, as determined by FINRA. Except as described in the Registration Statement and the Prospectus, the Company has not made
any direct or indirect payments (in cash, securities or otherwise) to: (i) any person, as a finder&rsquo;s fee, consulting fee or otherwise,
in consideration of such person raising capital for the Company or introducing to the Company persons who raised or provided capital
to the Company; (ii) to any FINRA member; or (iii) to any person or entity that has any direct or indirect affiliation or association
with any FINRA member, within the 180 days prior to the Effective Date. None of the Net Proceeds will be paid by the Company to any participating
FINRA member or its affiliates, except as specifically authorized herein. No officer, director or, to the Company&rsquo;s knowledge,
any beneficial owner of 5% or more of the Company&rsquo;s securities (whether debt or equity, registered or unregistered, regardless
of the time acquired or the source from which derived) (any such individual or entity, a &ldquo;<B><I>Company Affiliate</I></B>&rdquo;)
has any direct or indirect affiliation or association with any FINRA member (as determined in accordance with the rules and regulations
of FINRA); no Company Affiliate is an owner of stock or other securities of any member of FINRA (other than securities purchased on the
open market); no Company Affiliate has made a subordinated loan to any member of FINRA; and no Net Proceeds from the sale of the Shares
will be paid to any FINRA member, or any persons associated with or affiliated with any member of FINRA. Except as disclosed in the Registration
Statement and the Prospectus, the Company has not issued any warrants or other securities or granted any options, directly or indirectly,
to anyone who is a potential underwriter in the Offering or a related person (as defined by FINRA rules) of such an underwriter within
the 180-day period prior to the initial filing date of the Registration Statement; no person to whom securities of the Company have been
privately issued within the 180-day period prior to the initial filing date of the Registration Statement has any relationship or affiliation
or association with any member of FINRA; and no FINRA member participating in the offering has a conflict of interest with the Company.
For this purpose, a &ldquo;conflict of interest&rdquo; has the meaning ascribed to such term in FINRA Rule 5121(f)(5).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company has not distributed and will not distribute any prospectus or other offering material in connection with the Offering other
than the Registration Statement and the Prospectus or other materials permitted by the Securities Act to be distributed by the Company;
provided, however, that the Company has not made and will not make any offer relating to the Shares that would constitute a &ldquo;free
writing prospectus&rdquo; as defined in Rule 405 under the Securities Act, except any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Any certificate signed by any officer of the Company and delivered to the Agent or the Agent&rsquo;s counsel shall be deemed a representation
and warranty by the Company to Agent as to the matters covered thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
At each Bringdown Date and each Time of Sale, the Company shall be deemed to have affirmed each representation and warranty contained
in or made pursuant to this Agreement as of such date as though made at and as of such date (except that such representations and warranties
shall be deemed to relate to the Registration Statement and the Prospectus as amended and supplemented relating to such Shares on such
date).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
As used in this Agreement, references to matters being &ldquo;<B><I>material</I></B>&rdquo; with respect to the Company shall mean a
material event, change, condition, status or effect related to the condition (financial or otherwise), properties, assets (including
intangible assets), liabilities, business, prospects, operations or results of operations of the Company, either individually or taken
as a whole, as the context requires.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
As used in this Agreement, the term &ldquo;<B><I>to the Company&rsquo;s knowledge</I></B>&rdquo; (or similar language) shall mean the
knowledge of the executive officers and directors of the Company who are named in the Prospectus, with the assumption that such executive
officers and directors shall have made reasonable and diligent inquiry of the matters presented (with reference to what is customary
and prudent for the applicable individuals in connection with the discharge by the applicable individuals of their duties as executive
officers or directors of the Company).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
<B><I>Purchase, Sale and Delivery of Shares</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
<I>At the Market Sales</I>. On the basis of the representations, warranties and agreements herein the Company agrees that, from time
to time after the effectiveness of the Registration Statement, on the terms and subject to the conditions set forth herein, it may issue
and sell through the Agent, acting as sales agent, up to an aggregate of $9,000,000 of Shares (the &ldquo;<B><I>Maximum Amount</I></B>&rdquo;)
subject to the limitations required by General Instruction I.B.6 of Form S-3. Notwithstanding the foregoing, the Company agrees that
it will provide the Agent with written notice no less than one (1) business day prior to the date on which it makes the initial sale
of Shares under this Agreement, provided that such notice may not be provided prior to the effectiveness of the Registration Statement.
The Company acknowledges and agrees that it may not provide any instruction or notice to the Agent relating to the sale of the Shares
prior to the effectiveness of the Registration Statement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
Each time the Company wishes to issue and sell the Shares hereunder (each, a &ldquo;<B><I>Transaction</I></B>&rdquo;), it will notify
the Agent by telephone (confirmed promptly by e-mail to the appropriate individual listed on <U>Schedule D</U> hereto, using a form substantially
similar to that set forth on <U>Schedule C</U> hereto (a &ldquo;<B><I>Transaction Notice</I></B>&rdquo;) as to the maximum number of
Shares to be sold by the Agent on such day and in any event not in excess of the amount available for issuance under the Prospectus and
the currently effective Registration Statement, the time period during which sales are requested to be made, any limitation on the number
of shares that may be sold in any one Trading Day (as defined below), and any minimum price below which sales may not be made. The Transaction
Notice shall originate from any of the individuals from the Company set forth on <U>Schedule B</U> (with a copy to each of the other
individuals from the Company listed on such Schedule), and shall be addressed to each of the individuals from the Agent set forth on
<U>Schedule D</U>, as such <U>Schedule D</U> may be amended from time to time. Subject to the terms and conditions hereof and unless
the sale of the Shares described therein has been declined, suspended, or otherwise terminated in accordance with the terms of this Agreement,
the Agent shall promptly acknowledge the Transaction Notice by e-mail (or by some other method mutually agreed to in writing by the parties)
and shall use its commercially reasonable efforts to sell all of the Shares so designated by the Company, and in accordance with the
terms set forth herein, in the Transaction Notice; provided, however, that any obligation of the Agent to use such commercially reasonable
efforts shall be subject to the continuing accuracy of the representations and warranties of the Company herein, to the performance by
the Company of its obligations hereunder and to the continuing satisfaction of the additional conditions specified in <U>Section 4</U>.
The gross sales price of the Shares sold under this <U>Section 2(a)</U> shall be equal to the market price for the Common Stock sold
by the Agent under this <U>Section 2(a)</U> on the NASDAQ Capital Market at the time of such sale. For the purposes hereof, &ldquo;<B><I>Trading
Day</I></B>&rdquo; means any day on which shares of Common Stock are purchased and sold on the principal market on which the Common Stock
is listed or quoted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
The Company or the Agent may, upon notice to the other party hereto by telephone (confirmed promptly by e-mail to the respective individuals
of the other party set forth on <U>Schedule D</U> hereto, which confirmation shall be promptly acknowledged by the other party), suspend
the Offering for any reason and at any time, whereupon the Agent shall so suspend the offering of Shares until further notice is provided
by the other party to the contrary; <I>provided</I>, <I>however</I>, that such suspension or termination shall not affect or impair the
parties&rsquo; respective obligations with respect to the Shares sold hereunder prior to the receipt by the Agent of such notice. Each
of the parties agrees that no such notice under this <U>Section 2(a)(ii)</U> shall be effective against the other unless it is made to
one of the individuals named on <U>Schedule D</U> hereto, as such Schedule may be amended from time to time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Company acknowledges and agrees that (A) there can be no assurance that the Agent will be successful in selling the Shares, (B) the
Agent will incur no liability or obligation to the Company or any other person or entity if it does not sell Shares for any reason other
than a failure by the Agent to use its commercially reasonable efforts consistent with its normal trading and sales practices and applicable
law and regulations to sell such Shares as required under this Agreement, and (C) the Agent shall be under no obligation to purchase
shares on a principal basis pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
The Agent hereby covenants and agrees not to make any sales of the Shares on behalf of the Company, pursuant to this <U>Section 2(a)</U>,
other than by means of ordinary brokers&rsquo; transactions deemed to be &ldquo;at the market&rdquo; offerings as defined in Rule 415
of the Securities Act including without limitation sales made directly on the NASDAQ Capital Market, on any other existing trading market
for the Common Stock or to or through a market maker. With the prior written consent of the Company, which may be provided in a Transaction
Notice, the Agent may also sell Shares in privately negotiated transactions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The compensation to the Agent for sales of the Shares, as an agent of the Company, shall be 2.0% of the gross sales price of all of Shares
sold pursuant to this <U>Section 2(a)</U>. The remaining proceeds, after further deduction for any transaction fees imposed by any governmental
or self-regulatory organization in respect of such sales, shall constitute the net proceeds to the Company for such Shares (the &ldquo;<B><I>Net
Proceeds</I></B>&rdquo;). The Agent shall notify the Company as promptly as practicable if any deduction referenced in the preceding
sentence will be required.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vi)
The Agent shall provide written confirmation to the Company following the close of trading on the NASDAQ Capital Market each day in which
the Shares are sold under this <U>Section 2(a)</U> setting forth the number of the Shares sold on such day, the aggregate gross sale
proceeds, the Net Proceeds to the Company, and the compensation payable by the Company to the Agent with respect to such sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vii)
All Shares sold pursuant to this <U>Section 2(a)</U> will be delivered by the Company to Agent for the accounts of the Agent on the second
full business day following the date on which such Shares are sold, or at such other time and date as Agent and the Company determine
pursuant to Rule 15c6-1(a) under the Exchange Act, each such time and date of delivery being herein referred to as a &ldquo;<B><I>Settlement
Date</I></B>.&rdquo; On each Settlement Date, the Shares sold through the Agent for settlement on such date shall be issued and delivered
by the Company to the Agent against payment of the Net Proceeds from the sale of such Shares. Settlement for all such Shares shall be
effected by free delivery of the Shares by the Company or its transfer agent (i) to the Agent or its designee&rsquo;s account (provided
the Agent shall have given the Company written notice of such designee prior to the Settlement Date) at The Depository Trust Company
(&ldquo;<B><I>DTC</I></B>&rdquo;) or (ii) by such other means of delivery as may be mutually agreed upon by the parties hereto, which
in all cases shall be freely tradable, transferable, registered shares in good deliverable form, in return for payment in same day funds
delivered to an account designated by the Company. If the Company or its transfer agent (if applicable) shall default on its obligation
to deliver the Shares on any Settlement Date, the Company shall (A) indemnify and hold the Agent harmless against any loss, claim or
damage arising from or as a result of such default by the Company and (B) pay the Agent any commission to which it would otherwise be
entitled absent such default against payment of the Net Proceeds therefor by wire transfer of same day funds payable to the order of
the Company at 9:00 a.m. New York City time. If the Agent breaches this Agreement by failing to deliver the Net Proceeds on any Settlement
Date for the shares delivered by the Company, the Agent will pay the Company interest based on the effective prime rate until such proceeds,
together with such interest, have been fully paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(viii)
Under no circumstances shall the Company cause or request the offer or sale of any Shares if, after giving effect to the sale of such
Shares, (i) the aggregate gross sales proceeds sold pursuant to this Agreement would exceed the lesser of (A) together with all sales
of Shares under this Agreement, the Maximum Amount, (B) the amount available for offer and sale under the currently effective Registration
Statement and (C) the amount authorized from time to time to be issued and sold under this Agreement by the Company&rsquo;s board of
directors, a duly authorized committee thereof or a duly authorized executive committee, and notified to the Agent in writing or (ii)
the total amount of Common Stock outstanding would exceed the number of Common Stock authorized by the Company&rsquo;s Second Amended
and Restated Certificate of Incorporation. Under no circumstances shall the Company cause or request the offer or sale of any Shares
at a price lower than the minimum price authorized from time to time by the Company&rsquo;s board of directors, duly authorized committee
thereof or a duly authorized executive committee, and notified to the Agent in writing. Further, under no circumstances shall the aggregate
offering amount of Shares sold pursuant to this Agreement, including any separate underwriting or similar agreement covering principal
transactions, exceed the Maximum Amount.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ix)
The Company agrees that any offer to sell, any solicitation of an offer to buy, or any sales of Shares shall only be effected by or through
the Agent; provided, however, that the foregoing limitation shall not apply to the exercise of any outstanding option or warrant or conversion
of the convertible notes described in the Registration Statement and the Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
Nothing herein contained shall constitute the Agent an unincorporated association or partner with the Company. Under no circumstances
shall any Shares be sold pursuant to this Agreement after the date which is three years after the Registration Statement is first declared
effective by the Commission.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Notwithstanding any other provisions of this Agreement, the Company agrees that no sale of Shares shall take place, and the Company shall
not request the sale of any Shares, and the Agent shall not be obligated to sell, during any period in which the Company is, or could
be deemed to be, in possession of material non-public information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
<B><I><U>Covenants</U></I></B>. The Company covenants and agrees with the Agent as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
After the date hereof and through any Prospectus Delivery Period, prior to amending or supplementing the Registration Statement (including
any Rule 462(b) Registration Statement), Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, the Company shall
furnish to the Agent for review a copy of each such proposed amendment or supplement, allow the Agent a reasonable amount of time to
review and comment on such proposed amendment or supplement, and the Company shall not file any such proposed amendment or supplement
to which the Agent or counsel to the Agent reasonably object; provided that the foregoing shall not apply with regards to the filing
by the Company of any Form 10-K, 10-Q, 8-K, proxy statement or other Incorporated Document. Subject to this <U>Section 3(a)</U>, immediately
following execution of this Agreement, if not previously prepared, the Company will prepare a prospectus supplement describing the selling
terms of the Shares hereunder, the plan of distribution thereof and such other information as may be required by the Securities Act or
the Rules and Regulations or as the Agent and the Company may deem appropriate, and if requested by the Agent, a Permitted Free Writing
Prospectus containing the selling terms of the Shares hereunder and such other information as the Company and the Agent may deem appropriate,
and will file or transmit for filing with the Commission, in accordance with Rule 424(b) or Rule 433, as the case may be, copies of the
Prospectus as supplemented and each such Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
After the date of this Agreement, the Company shall promptly advise the Agent in writing (i) of the receipt of any comments of, or requests
for additional or supplemental information from, the Commission or for any amendments or supplements to the Registration Statement, the
Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus (excluding any Incorporated Documents), (ii) of the time and
date of any filing of any post-effective amendment to the Registration Statement or any amendment or supplement to any Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus(excluding any Incorporated Documents), (iii) of the time and date that any post-effective
amendment to the Registration Statement becomes effective, (iv) of the issuance by the Commission of any stop order suspending the effectiveness
of the Registration Statement or any post-effective amendment thereto or of any order preventing or suspending its use or the use of
any Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, or (v) of any proceedings to remove, suspend or terminate
from listing or quotation the Common Stock from any securities exchange upon which it is listed for trading or included or designated
for quotation, or of the threatening or initiation of any proceedings for any of such purposes. If the Commission shall enter any such
stop order at any time, the Company may terminate this Agreement. Additionally, the Company agrees that it shall comply with the provisions
of Rules 424(b), 430B and 430C, as applicable, under the Securities Act and will use its reasonable efforts to confirm that any filings
made by the Company under Rule 424(b), Rule 433 or Rule 462 were received in a timely manner by the Commission (without reliance on Rule
424(b)(8) or Rule 164(b)).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
From the date hereof through the later of (A) the termination of this Agreement and (B) the end of any applicable Prospectus Delivery
Period, the Company will comply in all material respects with all requirements imposed upon it by the Securities Act, as now and hereafter
amended, and by the Rules and Regulations, as from time to time in force, and by the Exchange Act so far as necessary to permit the continuance
of sales of or dealings in the Shares as contemplated by the provisions hereof, the Base Prospectus, the Prospectus and any Permitted
Free Writing Prospectus. If during any applicable Prospectus Delivery Period any event occurs as a result of which the Base Prospectus,
the Prospectus, or any Permitted Free Writing Prospectus would include an untrue statement of a material fact or omit to state a material
fact necessary to make the statements therein, in the light of the circumstances then existing, not misleading, or if during any applicable
Prospectus Delivery Period it is necessary or appropriate in the opinion of the Company or its counsel or in the reasonable opinion of
the Agent or counsel to the Agent to amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted
Free Writing Prospectus, to comply with the Securities Act or to file under the Exchange Act any document which would be deemed to be
incorporated by reference in the Prospectus in order to comply with the Securities Act or the Exchange Act, the Company will promptly
notify Agent (or the Agent will notify the Company, as applicable), and the Agent shall suspend the offering and sale of any such Shares,
and the Company will amend the Registration Statement or supplement the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus or file such document (at the expense of the Company) so as to correct such statement or omission or effect such compliance
within the time period prescribed by the Securities Act or the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
In case the Agent is required to deliver (whether physically or through compliance with Rule 172 under the Securities Act or any similar
rule), in connection with the sale of the Shares, a Prospectus after the nine-month period referred to in Section 10(a)(3) of the Securities
Act, or after the time a post-effective amendment to the Registration Statement is required pursuant to Item 512(a) of Regulation S-K
under the Securities Act, the Company will prepare, at its expense, promptly upon request such amendment or amendments to the Registration
Statement and the Prospectus as may be necessary to permit compliance with the requirements of Section 10(a)(3) of the Securities Act
or Item 512(a) of Regulation S-K under the Securities Act, as the case may be. The Company shall cause each amendment or supplement to
any Base Prospectus or the Prospectus to be filed with the Commission as required pursuant to the applicable paragraph of Rule 424(b)
of the Securities Act or, in the case of any document which would be deemed to be incorporated by reference therein, to be filed with
the Commission as required pursuant to the Exchange Act, within the time period prescribed. The Company shall promptly notify the Agent
if any Material Contract is terminated or if the other party thereto gives written notice of its intent to terminate any such Material
Contract.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If at any time following issuance of a Permitted Free Writing Prospectus there occurs an event or development as a result of which such
Permitted Free Writing Prospectus would conflict with the information contained in the Registration Statement, the Base Prospectus or
the Prospectus, or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances prevailing at that subsequent time, not misleading, the Company
promptly will notify the Agent and will promptly amend or supplement, at its own expense, such Permitted Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or .</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall use commercially reasonable efforts to take or cause to be taken all necessary action to qualify the Shares for sale
under the securities laws of such jurisdictions as Agent reasonably designates and to continue such qualifications in effect so long
as required for the distribution of the Shares, except that the Company shall not be required in connection therewith to qualify as a
foreign corporation or to execute a general consent to service of process in any state. The Company shall promptly advise the Agent of
the receipt by the Company of any notification with respect to the suspension of the qualification of the Shares for offer or sale in
any jurisdiction or the initiation or threatening of any proceeding for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company will furnish to the Agent and counsel for the Agent, to the extent requested, copies of the Registration Statement, the Base
Prospectus, the Prospectus, any Permitted Free Writing Prospectus, and all amendments and supplements to such documents, in each case
as soon as available and in such quantities as the Agent may from time to time reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company will make generally available to its security holders as soon as practicable an earnings statement (which need not be audited)
covering a 12-month period that shall satisfy the provisions of Section 11(a) of the Securities Act and Rule 158 of the Rules and Regulations.
If the Company makes any public announcement or release disclosing its results of operations or financial condition for a completed quarterly
or annual fiscal period (each, an &ldquo;<B><I>Earnings Release</I></B>&rdquo;) and the Company has not yet filed an Annual Report on
Form 10-K or a Quarterly Report on Form 10-Q or a Form 8-K with respect to such information, as applicable, then, prior to any sale of
Shares, the Company shall be obligated to (x) file a prospectus supplement with the Commission under the applicable paragraph of Rule
424(b), which prospectus supplement shall include the applicable financial information or (y) file a Report on Form 8-K, which Form 8-K
shall include the applicable financial information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
The Company, whether or not the transactions contemplated hereunder are consummated or this Agreement is terminated, will pay or cause
to be paid (i) all expenses (including stock or transfer taxes and stamp or similar duties allocated to the respective transferees) incurred
in connection with the registration, issue, sale and delivery of the Shares, (ii) all reasonable expenses and fees (including, without
limitation, fees and expenses of the Company&rsquo;s accountants and counsel) in connection with the preparation, printing, filing, delivery,
and shipping of the Registration Statement (including the financial statements therein and all amendments, schedules, and exhibits thereto),
the Base Prospectus, each Prospectus, any Permitted Free Writing Prospectus, and any amendment thereof or supplement thereto, and the
producing, word-processing, printing, delivery, and shipping of this Agreement and other closing documents, including blue sky memoranda
(covering the states and other applicable jurisdictions) and including the cost to furnish copies of each thereof to the Agent, (iii)
all filing fees, (iv) listing fees, if any, (v) the cost and expenses of the Company relating to investor presentations or any &ldquo;roadshow&rdquo;
undertaken in connection with marketing of the Shares as agreed to by the Company, and (vi) all other costs and expenses of the Company
incident to the performance of its obligations hereunder that are not otherwise specifically provided for herein. The Company will reimburse
the Agent upon request for its actual, reasonable and documented costs and out-of-pocket expenses incurred in connection with this Agreement,
including the actual, reasonable and documented fees and out-of-pocket expenses of its legal counsel in an amount not to exceed an aggregate
of $50,000. The Company shall bear and be responsible for all expenses which are customarily borne by issuers for transactions of the
type set forth herein. In the event that the proposed Offering is terminated by the Company for any reason, the Company shall reimburse
the actual, reasonable, documented and accountable costs and expenses incurred by the Agent in connection with its engagement with respect
to the Offering, including legal fees and out-of-pocket expenses; provided that any previous payments made by the Company for such costs,
fees and expenses shall be credited against the reimbursement due to the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
The Company will apply the net proceeds from the sale of the Shares in the manner set forth under the caption &ldquo;Use of Proceeds&rdquo;
in the Base Prospectus, the Prospectus, and any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company will not, without (1) giving the Agent at least three business days&rsquo; prior written notice specifying the nature of
the proposed sale and the date of such proposed sale, and (2) the Agent suspending activity under this Agreement for such period of time
as requested by the Company, offer for sale, sell, contract to sell, pledge, grant any option for the sale of, enter into any transaction
which is designed to, or might reasonably be expected to, result in the disposition (whether by actual disposition or effective economic
disposition due to cash settlement or otherwise) by the Company, or otherwise issue or dispose of, directly or indirectly (or publicly
disclose the intention to make any such offer, sale, pledge, grant, issuance or other disposition), of any Common Stock or any securities
convertible into or exchangeable for, or any options or rights to purchase or acquire, Common Stock, or permit the registration under
the Securities Act of any Common Stock, such securities, options or rights, except for (i) the registration of the Shares and the sales
through the Agent pursuant to this Agreement (ii) the registration of outstanding Common Stock for resale, (iii) the registration of
Common Stock issued or issuable with respect to any currently outstanding options, convertible notes and warrants that are described
in the Registration Statement and the Prospectus, (iv) a registration statement on Form S-8 relating to employee benefit plans (v) the
issuance of Common Stock in connection with a bona fide acquisition from a third party, (vi) the issuance of Common Stock or any securities
convertible into or exchangeable for, or any options or rights to purchase or acquire Common Stock in any private placement(s), (vii)
the issuance of Common Stock or any securities convertible into or exchangeable for, or any options or rights to purchase or acquire
Common Stock pursuant to any agreement or transaction of which the primary purpose is not to raise capital, and (viii) the issuance of
Common Stock or any securities convertible into or exchangeable for, or any options or rights to purchase or acquire Common Stock pursuant
to the Company&rsquo;s equity incentive plans or employee stock purchase plans described in the Registration Statement, or the Prospectus.
Notwithstanding the foregoing, the Company may not engage in any other at-the-market equity offering during the term of this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
The Company shall not, at any time at or after the execution of this Agreement, offer or sell any Shares by means of any &ldquo;prospectus&rdquo;
(within the meaning of the Securities Act), or use any &ldquo;prospectus&rdquo; (within the meaning of the Securities Act) in connection
with the offer or sale of the Shares, in each case other than the Prospectus or any Permitted Free Writing Prospectus.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)
The Company has not taken and will not take, directly or indirectly, any action designed to or which might reasonably be expected to
cause or result in, or which has constituted, (i) the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of the Shares or (ii) a violation of Regulation M. The Company shall notify the Agent of any violation of Regulation
M by the Company or any of its officers or directors promptly after the Company has received notice or obtained knowledge of any such
violation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)
The Company will not incur any liability for any finder&rsquo;s or broker&rsquo;s fee or agent&rsquo;s commission in connection with
the execution and delivery of this Agreement or the consummation of the transactions contemplated hereby or thereby, except as contemplated
herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)
During any applicable Prospectus Delivery Period, the Company will file on a timely basis with the Commission such periodic and current
reports as required by the Rules and Regulations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)
The Company has maintained, and will maintain, such controls and procedures, including without limitation those required by Sections
302 and 906 of Sarbanes-Oxley and the applicable regulations thereunder, that are designed to ensure that information required to be
disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported
within the time periods specified in the Commission&rsquo;s rules and forms, including without limitation, controls and procedures designed
to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is
accumulated and communicated to the Company&rsquo;s management, including its principal executive officer and its principal financial
officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure, to ensure that
material information relating to Company is made known to them by others within those entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)
[Intentionally Omitted.]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)
Each of the Company and Agent represent and agree that, neither the Company nor the Agent has made and will make any offer relating to
the Shares that would constitute an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433 under the Securities Act, or
that would otherwise constitute a &ldquo;free writing prospectus,&rdquo; as defined in Rule 405 under the Securities Act, required to
be filed with the Commission other than a Permitted Free Writing Prospectus. The Company represents that it has treated or agrees that
it will treat each Permitted Free Writing Prospectus as an &ldquo;issuer free writing prospectus,&rdquo; as defined in Rule 433, and
has complied and will comply with the requirements of Rule 433 applicable to any Permitted Free Writing Prospectus, including timely
Commission filing where required, legending and record keeping.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)
On the date of this Agreement and on each date that the Company (i) amends or supplements the Registration Statement or the Prospectus
(other than by means of incorporation by reference); (ii) files an annual report on Form 10-K under the Exchange Act; (iii) files a report
on Form 10-Q under the Exchange Act containing quarterly financial statements; or (iv) files a report on Form 8-K under the Exchange
Act containing amended financial information (each of such date referred to herein as a &ldquo;<B><I>Bringdown Date</I></B>&rdquo;),
the Company shall cause The McGeary Law Firm P.C., counsel for the Company, to furnish to the Agent its written opinion and negative
assurance letter, in form and substance stating in effect the matters set forth on <U>Annex A</U> hereto. With respect to this <U>Section
3(q)</U>, in lieu of delivering such opinions or letters for Bringdown Dates subsequent to the date of effectiveness of the Registration
Statement, such counsel may furnish agent with a letter (a &ldquo;<B><I>Reliance Letter</I></B>&rdquo;) to the effect that Agent may
rely upon a prior opinion or letter delivered under this <U>Section 3(q)</U> to the same extent as if it were dated the date of such
letter (except that statement in such prior opinion shall be deemed to relate to the Registration Statement and the Prospectus as amended
or supplemented as of the date of Reliance Letter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided,
however, the requirement to provide opinions and letters under this <U>Section 3(q)</U> is hereby waived for any Bringdown Date occurring
at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date the Company delivers
a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company subsequently decides
to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide Agent with opinions and letters
under this <U>Section 3(q)</U>, then before the Company delivers the Transaction Notice or Agent sells any Shares, the Company shall
cause The McGeary Law Firm to furnish to the Agent a written opinion and negative assurance letter dated the date of the Transaction
Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)
On the date of this Agreement and on each Bringdown Date, the Company shall cause the Auditor, or other independent accountants satisfactory
to the Agent, to deliver to the Agent (x) a letter addressed to Agent, in form and substance satisfactory to Agent (the first such letter,
the &ldquo;<B><I>Initial Comfort Letter</I></B>&rdquo;), confirming that they are independent public accountants within the meaning of
the Securities Act and are in compliance with the applicable requirements relating to the qualifications of accountants under Rule 2-01
of Regulation S-X of the Commission, and stating the conclusions and findings of said firm with respect to the financial information
and other matters and (y) a letter updating the Initial Comfort Letter with any information that would have been included in the Initial
Comfort Letter had it been given on such date and as modified as necessary to relate to the date of such letter (each such letter, a
&ldquo;<B><I>Bringdown Comfort Letter</I></B>&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided,
however, the requirement to provide a Bringdown Comfort Letter under this <U>Section 3(r)</U> is hereby waived for any Bringdown Date
occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date the
Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company
subsequently decides to sell Shares following a Bringdown Date when the Company relied on such waiver and did not provide Agent with
a Bringdown Comfort Letter under this <U>Section 3(r)</U>, then before the Company delivers the Transaction Notice or Agent sells any
Shares, the Company shall cause the Auditor, or other independent accountants satisfactory to the Agent, to deliver to the Agent a Bringdown
Comfort Letter dated the date of the Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)
On the date hereof, each Bringdown Date, and each date when the Company (A) amends or supplements (other than a supplement to a Prospectus
filed pursuant to Rule 424(b) under the Securities Act relating solely to the offering of securities other than the Shares ) the Registration
Statement or Prospectus by means of a post-effective amendment, sticker, or supplement but not by means of incorporation of documents
by reference into the Registration Statement or the Prospectus relating to the Shares, (B) files an annual report on Form 10-K under
the Exchange Act (including any Form 10-K/A containing amended material financial information or a material amendment to the previously
filed Form 10-K), (C) files a quarterly report on Form 10-Q under the Exchange Act (including any Form 10-Q/A containing amended material
financial information or a material amendment to the previously filed Form 10-Q) or (D) files a current report on Form 8-K containing
financial information that is incorporated by reference in the Registration Statement and Prospectus (each of the dates in (A) through
(D) are referred to herein as a &ldquo;<B><I>Supplement Date</I></B>&rdquo;), the Company shall furnish to the Agent a certificate addressed
to Agent, signed by the chief executive officer and by the chief financial officer of the Company, to the effect that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The representations and warranties of the Company in this Agreement are true and correct in all material respects as if made at and as
of the date of the certificate, and the Company has complied in all material respects with all the agreements and satisfied all the conditions
on its part to be performed or satisfied at or prior to the date of the certificate;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
No stop order or other order suspending the effectiveness of the Registration Statement or any part thereof or any amendment thereof
or the qualification of the Shares for offering or sale or notice that would prevent use of the Registration Statement, nor suspending
or preventing the use of the Base Prospectus, the Prospectus or any Permitted Free Writing Prospectus, has been issued, and no proceeding
for that purpose has been instituted or, to the best of their knowledge, is contemplated by the Commission or any state or regulatory
body;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
The Shares to be sold on that date have been duly and validly authorized by the Company and all corporate action required to be taken
for the authorization, issuance and sale of the Shares on that date has been validly and sufficiently taken;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iv)
Subsequent to the respective dates as of which information is given in the Base Prospectus, the Prospectus or any Permitted Free Writing
Prospectus, as amended and supplemented, and except for pending transactions disclosed therein, the Company has not incurred any material
liabilities or obligations, direct or contingent, or entered into any material transactions, not in the ordinary course of business,
or declared or paid any dividends or made any distribution of any kind with respect to its capital stock, and there has not been any
change in the capital stock or any issuance of options, warrants, convertible securities or other rights to purchase the capital stock
(other than as a result of the exercise of any currently outstanding options or warrants that are disclosed in the Registration Statement
or the Prospectus or the issuance of securities pursuant to the Company&rsquo;s equity incentive plans or employee stock purchase plans
described in the Registration Statement or the Prospectus), or any material change in the short-term or long-term debt, of the Company,
or any Material Adverse Effect or any development that would reasonably be likely to result in a Material Adverse Effect (whether or
not arising in the ordinary course of business), or any material loss by strike, fire, flood, earthquake, accident or other calamity,
whether or not covered by insurance, incurred by the Company; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
Except as stated in the Prospectus and any Permitted Free Writing Prospectus, as amended and supplemented, there is not pending, or,
to the knowledge of the Company, threatened or contemplated, any action, suit or proceeding to which the Company is a party before or
by any court or governmental agency, authority or body, or any arbitrator, which would reasonably be likely to result in any Material
Adverse Effect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">provided,
however, the requirement to provide a certificate under this <U>Section 3(s)</U> is hereby waived for any Bringdown Date or Supplement
Date occurring at a time at which no Transaction Notice is pending, which waiver shall continue until the earlier to occur of the date
the Company delivers a Transaction Notice hereunder and the next occurring Bringdown Date. Notwithstanding the foregoing, if the Company
subsequently decides to sell Shares following a Bringdown Date or Supplement Date when the Company relied on such waiver and did not
provide Agent with a certificate under this <U>Section 3(s)</U>, then before the Company delivers the Transaction Notice or Agent sells
any Shares, the Company shall provide Agent with a certificate dated the date of the Transaction Notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)
A reasonable time prior to each Bringdown Date and each Supplement Date, the Company, if so requested by the Agent, shall conduct a due
diligence session, in form and substance, satisfactory to the Agent, which shall include representatives of the management and the accountants
of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)
The Company shall disclose in its annual report on Form 10-K and its quarterly reports on Form 10-Q the number of Shares sold through
the Agent under this Agreement, the Net Proceeds to the Company and the compensation paid by the Company with respect to sales of the
Shares pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)
The Company shall ensure that there are at all times sufficient shares of Common Stock to provide for the issuance, free of any preemptive
rights, out of its authorized but unissued Common Stock, of the maximum aggregate number of Shares authorized for issuance by the Board
pursuant to the terms of this Agreement. The Company will use its reasonable best efforts to cause the Shares to be listed on the NASDAQ
Capital Market, and to maintain such listing. The Company shall cooperate with Agent and use its reasonable efforts to permit Shares
to be eligible for clearance and settlement through the facilities of DTC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)
At any time during the term of this Agreement, the Company will advise the Agent promptly after it receives notice or obtains knowledge
of any information or fact that would alter or affect any opinion, certificate, letter and other document provided to the Agent pursuant
to <U>Section 3</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)
Subject to compliance with any applicable requirements of Regulation M under the Exchange Act and compliance with applicable securities
laws, the Company consents to the Agent trading in the Common Stock for the Agent&rsquo;s own account and for the account of its clients
(in compliance with all applicable laws) at the same time as sales of the Shares occur pursuant to this Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)
If to the knowledge of the Company, any condition set forth in <U>Section 4(a)</U> or <U>4(b)</U> shall not have been satisfied on the
applicable Settlement Date, the Company will offer to any person who has agreed to purchase the Shares on such Settlement Date from the
Company as the result of an offer to purchase solicited by the Agent the right to refuse to purchase and pay for such Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)
On the date hereof and each Bringdown Date, the Company shall furnish to the Agent an incumbency certificate, dated as of such date and
addressed to Agent, signed by the secretary of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
<B><I>Conditions of Agent&rsquo;s Obligations</I></B>. The obligations of the Agent hereunder are subject to (i) the accuracy of, as
of the date hereof, each Bringdown Date, and each Time of Sale (in each case, as if made at such date), and compliance with, all representations,
warranties and agreements of the Company contained herein, (ii) the performance by the Company of its obligations hereunder and (iii)
the following additional conditions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
If filing of the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing Prospectus, is required under the
Securities Act or the Rules and Regulations, the Company shall have filed the Prospectus (or such amendment or supplement) or such Permitted
Free Writing Prospectus with the Commission in the manner and within the time period so required (without reliance on Rule 424(b)(8)
or Rule 164(b)); the Registration Statement shall remain effective; no stop order suspending the effectiveness of the Registration Statement
or any part thereof, any Rule 462(b) Registration Statement, or any amendment thereof, nor suspending or preventing the use of the Base
Prospectus, the Prospectus or any Permitted Free Writing Prospectus shall have been issued; no proceedings for the issuance of such an
order shall have been initiated or threatened; and any request of the Commission for additional information (to be included in the Registration
Statement, the Base Prospectus, the Prospectus, any Permitted Free Writing Prospectus or otherwise) shall have been complied with to
the Agent&rsquo;s satisfaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Agent shall not have advised the Company that the Registration Statement, the Base Prospectus, the Prospectus, or any amendment or
supplement thereto, or any Permitted Free Writing Prospectus, contains an untrue statement of fact which, in the Agent&rsquo;s opinion,
is material, or omits to state a fact which, in the Agent&rsquo;s opinion, is material and is required to be stated therein or is necessary
to make the statements therein (i) with respect to the Registration Statement, not misleading and (ii) with respect to the Base Prospectus,
the Prospectus or any Permitted Free Writing Prospectus, in light of the circumstances under which they were made, not misleading.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
Except as set forth or contemplated in the Prospectus and any Permitted Free Writing Prospectus, subsequent to the respective dates as
of which information is given therein, the Company shall not have incurred any material liabilities or obligations, direct or contingent,
or entered into any material transactions, or declared or paid any dividends or made any distribution of any kind with respect to its
capital stock and there shall not have been any change in the capital stock, or any issuance of options, warrants, convertible securities
or other rights to purchase the capital stock (other than as a result of the exercise of any currently outstanding options or warrants
that are disclosed in the Registration Statement or the Prospectus or the issuance of securities pursuant to the Company&rsquo;s equity
incentive plans or employee stock purchase plans described in the Registration Statement or the Prospectus), or any material change in
the short-term or long-term debt, of the Company, or any Material Adverse Effect or any development that would be reasonably likely to
result in a Material Adverse Effect (whether or not arising in the ordinary course of business), or any material loss by strike, fire,
flood, earthquake, accident or other calamity, whether or not covered by insurance, incurred by the Company, the effect of which, in
any such case described above, in the Agent&rsquo;s judgment, makes it impractical or inadvisable to offer or deliver the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
The Company shall have performed each of its obligations under <U>Section 3(q)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)
The Company shall have performed each of its obligations under <U>Section 3(r)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)
The Company shall have performed each of its obligations under <U>Section 3(s)</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)
FINRA shall have raised no objection to the fairness and reasonableness of the underwriting terms and arrangements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)
All filings with the Commission required by Rule 424 under the Securities Act to have been filed by the Settlement Date shall have been
made within the applicable time period prescribed for such filing by Rule 424.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Company shall have furnished to Agent and the Agent&rsquo;s counsel such additional documents, certificates and evidence as they
may have reasonably requested.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)
Trading in the Common Stock shall not have been suspended on the NASDAQ Capital Market. The Shares shall have been listed and authorized
for trading on the NASDAQ Capital Market prior to the first Settlement Date, and satisfactory evidence of such actions shall have been
provided to the Agent and its counsel, which may include oral confirmation from a representative of the NASDAQ Capital Market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
such opinions, certificates, letters and other documents will be in compliance with the provisions hereof only if they are reasonably
satisfactory in form and substance to Agent and the Agent&rsquo;s counsel. The Company will furnish Agent with such conformed copies
of such opinions, certificates, letters and other documents as Agent shall reasonably request.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
<B><I>Indemnification and Contribution</I></B>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)
The Company agrees to indemnify and hold harmless the Agent and each of the other Indemnified Parties (as defined below) from and against
any losses, claims, damages, obligations, penalties, judgments, awards, liabilities, costs, expenses and disbursements, and any and all
actions suits proceedings and investigations in respect thereof and any and all legal and other costs, expenses and disbursements in
giving testimony or furnishing documents in response to subpoena or otherwise (including, without limitation, the costs, expenses and
disbursements, as and when incurred, of investigating, preparing, pursuing or defending any such action, suit, proceeding or investigation
(whether or not in connection with litigation in which any Indemnified Party is a party)) (collectively, &ldquo;<B><I>Losses</I></B>&rdquo;),
directly or indirectly, caused by, relating to, based upon, arising out of , or in connection with this Agreement, including, without
limitation, any act or omission by the Agent in connection with its acceptance of or the performance or non-performance of its obligations
under the Agreement, any breach by the Company of any representation, warranty, covenant or agreement contained in the Agreement (or
in any instrument, document or agreement relating thereto, including any agency agreement), or the enforcement by the Agent of its rights
under the Agreement or these indemnification provisions, except to the extent that any such Losses are found in a final judgment by a
court of competent jurisdiction (not subject to further appeal) to have resulted primarily and directly from the gross negligence or
willful misconduct of the Indemnified Party seeking indemnification hereunder. The Company also agrees that no Indemnified Party shall
have any liability (whether direct or indirect, in contract or tort or otherwise) to the Company for or in connection with this Agreement
for any other reason, except to the extent that any such liability is found in a final judgment by a court of competent jurisdiction
(not subject to further appeal) to have resulted primarily and directly from such Indemnified Party&rsquo;s gross negligence or willful
misconduct This indemnity agreement will be in addition to any liability that the Company otherwise might have.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
These indemnification provisions shall extend to the following persons (collectively, the &ldquo;<B><I>Indemnified Parties</I></B>&rdquo;):
the Agent, its present and former affiliated entities, managers, members, officers, employees, legal counsel, agents and controlling
persons (within the meaning of the federal securities laws), and the officers, directors, partners, stockholders, members, managers,
employees, legal counsel, agents and controlling persons of any of them. These indemnification provisions shall be in addition to any
liability which the Company may otherwise have to any Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)
If any action, suit, proceeding or investigation is commenced, as to which an Indemnified Party proposes to demand indemnification, it
shall notify the Company with reasonable promptness; <U>provided</U>, <U>however</U>, that any failure by an Indemnified Party to notify
the Company shall not relieve the Company from its obligations hereunder except to the extent that the Company is actually and materially
prejudiced by such failure to notify. An Indemnified Party shall have the right to retain counsel of its own choice to represent it,
and the fees, expenses and disbursements of such counsel shall be borne by the Company. Any such counsel shall, to the extent consistent
with its professional responsibilities, cooperate with the Company and any counsel designated by the Company. The Company shall be liable
for any settlement of any claim against any Indemnified Party made with the Company&rsquo;s written consent. The Company shall not, without
the prior written consent of the Agent, settle or compromise any claim, or permit a default or consent to the entry of any judgment in
respect thereof, unless such settlement, compromise or consent (i) includes, as an unconditional term thereof, the giving by the claimant
to all of the Indemnified Parties of an unconditional release from all liability in respect of such claim, and (ii) does not contain
any factual or legal admission by or with respect to an Indemnified Party or an adverse statement with respect to the character, professionalism,
expertise or reputation of any Indemnified Party or any action or inaction of any Indemnified Party.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(iii)
In order to provide for just and equitable contribution, if a claim for indemnification pursuant to these indemnification provisions
is made but it is found in a final judgment by a court of competent jurisdiction (not subject to further appeal) that such indemnification
may not be enforced in such case, even though the express provisions hereof provide for indemnification in such case, then the Company
shall contribute to the Losses to which any Indemnified Party may be subject (i) in accordance with the relative benefits received by
the Company and its stockholders, subsidiaries and affiliates, on the one hand, and the Indemnified Party, on the other hand, and (ii)
if (and only if) the allocation provided in clause (i) of this sentence is not permitted by applicable law, in such proportion as to
reflect not only the relative benefits, but also the relative fault of the Company, on the one hand, and the Indemnified Party, on the
other hand, in connection with the statements, acts or omissions which resulted in such Losses as well as any relevant equitable considerations.
No person found liable for a fraudulent misrepresentation shall be entitled to contribution from any person who is not also found liable
for fraudulent misrepresentation. The relative benefits received (or anticipated to be received) by the Company and its stockholders,
subsidiaries and affiliates shall be deemed to be equal to the aggregate consideration payable or receivable by such parties in connection
with the transaction or transactions to which the Agreement relates relative to the amount of fees actually received by the Agent in
connection with such transaction or transactions. Notwithstanding the foregoing, in no event shall the amount contributed by all Indemnified
Parties exceed the amount of fees previously received by the Agent pursuant to the Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)
The Agent will indemnify and hold harmless the Company and its affiliates and directors and each officer of the Company who signed the
Registration Statement and each person, if any, who controls the Company within the meaning of Section 15 of the Securities Act or Section
20 of the Exchange Act (the &ldquo;<B><I>Company Indemnified Parties</I></B>&rdquo;) from and against any Losses to which the Company
or the Company Indemnified Parties may become subject, under the Securities Act or otherwise (including in settlement of any litigation,
if such settlement is effected with the written consent of the Agent), insofar as such losses, claims, damages or liabilities (or actions
in respect thereof) arise out of or are based upon an untrue statement or omission or alleged untrue statement or omission of a material
fact contained in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto or any Permitted
Free Writing Prospectus, to the extent, that such untrue statement or alleged untrue statement or omission or alleged omission was made
in the Registration Statement, any Base Prospectus, the Prospectus, or any amendment or supplement thereto, or any Permitted Free Writing
Prospectus in reliance upon and in conformity with written information furnished to the Company by Agent expressly for use in the preparation
thereof, it being understood and agreed that the only information furnished by the Agent consists of the information described as such
in <U>Section 5(b)(ii)</U>, by the Company in connection with investigating or defending against any such loss, claim, damage, liability
or action.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)
The Agent confirms and the Company acknowledges that as of the date hereof no information has been furnished in writing to the Company
by or on behalf of the Agent specifically for inclusion in the Registration Statement, any Base Prospectus, the Prospectus or any Permitted
Free Writing Prospectus, other than information about the Agent included in the Prospectus Supplement under the heading &ldquo;Plan of
Distribution&rdquo;.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)
If the indemnification provided for in this <U>Section 5</U> is unavailable or insufficient to hold harmless an indemnified party under
subsection (a) or (b) above, then each indemnifying party shall contribute to the amount paid or payable by such indemnified party as
a result of the losses, claims, damages or liabilities referred to in subsection (a) or (b) above, (i) in such proportion as is appropriate
to reflect the relative benefits received by the Company on the one hand and the Agent on the other from the Offering or (ii) if the
allocation provided by clause (i) above is not permitted by applicable law, in such proportion as is appropriate to reflect not only
the relative benefits referred to in clause (i) above but also the relative fault of the Company on the one hand and the Agent on the
other in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other
relevant equitable considerations. The relative benefits received by the Company on the one hand and the Agent on the other shall be
deemed to be in the same proportion as the total net proceeds from the Offering (before deducting expenses) received by the Company and
the total underwriting discounts and commissions received by the Agent, bear to the total public offering price of the Shares. The relative
fault shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the
omission or alleged omission to state a material fact relates to information supplied by the Company or the Agent and the parties&rsquo;
relevant intent, knowledge, access to information and opportunity to correct or prevent such untrue statement or omission. The Company
and the Agent agree that it would not be just and equitable if contributions pursuant to this subsection (c) were to be determined by
pro rata allocation or by any other method of allocation which does not take account of the equitable considerations referred to in the
first sentence of this subsection (c). The amount paid by an indemnified party as a result of the losses, claims, damages or liabilities
referred to in the first sentence of this subsection (c) shall be deemed to include any legal or other expenses reasonably incurred by
such indemnified party in connection with investigating or defending against any action or claim which is the subject of this subsection
(c). Notwithstanding the provisions of this subsection (c), the Agent shall not be required to contribute any amount in excess of the
amount by which the total price at which the Shares underwritten by it and distributed to the public were offered to the public exceeds
the amount of any damages that the Agent has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission
or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) shall
be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
Neither the termination of this Agreement nor completion of the Offering shall affect these indemnification provisions, which shall remain
operative and in full force and effect. The indemnification provisions shall be binding upon the Company and the Agent and their respective
successors and assigns and shall inure to the benefit of the Indemnified Parties and the Company Indemnified Parties and their respective
successors, assigns, heirs and personal representatives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
<B><I>Representations and Agreements to Survive Delivery</I></B>. All representations and warranties of the Company herein or in certificates
delivered pursuant hereto, and agreements of the Agent and the Company herein, including but not limited to the agreements of the Agent
and the Company contained in <U>Section 5</U>, shall remain operative and in full force and effect regardless of any investigation made
by or on behalf of the Agent or any controlling person thereof, or the Company or any of its officers, directors, or controlling persons,
and shall survive delivery of, and payment for, the Shares to and by the Agent hereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
<B><I>Termination of this Agreement</I></B>. The term of this Agreement shall begin on the date hereof, and shall continue until the
earlier of (i) the sale of Shares having an aggregate offering price of $9,000,000 or (ii) the termination by either the Agent or the
Company upon the provision of five (5) days written notice. Any such termination by mutual agreement shall in all cases be deemed to
provide that Section 3(g), Section 3(o) Section 5 and Section 6 shall remain in full force and effect.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
<B><I>Default by the Company</I></B>. If the Company shall fail at any Settlement Date to sell and deliver the number of Shares which
it is obligated to sell hereunder, then this Agreement shall terminate without any liability on the part of the Agent or, except as provided
in <U>Section 3(g)</U>, any non-defaulting party. No action taken pursuant to this <U>Section 8</U> shall relieve the Company from liability,
if any, in respect of such default, and the Company shall (A) hold the Agent harmless against any loss, claim or damage arising from
or as a result of such default by the Company and (B) pay the Agent any commission to which it would otherwise be entitled absent such
default.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
<B><I>Notices</I></B>. Except as otherwise provided herein, all communications under this Agreement shall be in writing and, if to the
Agent, shall be mailed, delivered or telecopied to EF Hutton, a division of Benchmark Investments, LLC, 590 Madison Avenue, 39th Floor
New York, New York 10022, (email:dboral@efhuttongroup.com), Attention: David Boral, President with a required copy (which shall not constitute
notice) to Loeb &amp; Loeb LLP, 345 Park Avenue, New York, New York 10154 (email: mnussbaum@loeb.com) Attention: Mitchell S. Nussbaum,
Esq. Notices to the Company shall be given to it at 3840 Land O&rsquo; Lakes Boulevard, Land O&rsquo; Lakes, Florida 34639 Attention:
Chief Executive Officer, (email: suren@trxade.com) with required copies (which shall not constitute notice) to The Loev Law Firm,
P.C. 6300 West Loop South, Suite 280, Bellaire, TX 77401, (email:dloev@loevlaw.com) Attention: David Loev. Any party to this Agreement
may change such address for notices by sending to the parties to this Agreement written notice of a new address for such purpose.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
<B><I>Persons Entitled to Benefit of Agreement</I></B>. This Agreement shall inure to the benefit of and be binding upon the parties
hereto and their respective successors and assigns and the controlling persons, officers and directors referred to in <U>Section 5</U>.
Nothing in this Agreement is intended or shall be construed to give to any other person, firm or corporation any legal or equitable remedy
or claim under or in respect of this Agreement or any provision herein contained. The term &ldquo;successors and assigns&rdquo; as herein
used shall not include any purchaser, as such purchaser, of any of the Shares from the Agent.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
<B><I>Absence of Fiduciary Relationship</I></B>. The Company acknowledges and agrees that: (a) the Agent has been retained solely to
act as an sales agent and/or principal in connection with the sale of the Shares and that no fiduciary, advisory or agency relationship
between the Company and the Agent has been created in respect of any of the transactions contemplated by this Agreement, irrespective
of whether the Agent has advised or are advising the Company on other matters; (b) the price and other terms of the Shares set forth
in this Agreement were established by the Company following discussions and arms-length negotiations with the Agent and the Company is
capable of evaluating and understanding and understands and accepts the terms, risks and conditions of the transactions contemplated
by this Agreement; (c) it has been advised that the Agent and its affiliates are engaged in a broad range of transactions which may involve
interests that differ from those of the Company and that the Agent has no obligation to disclose such interest and transactions to the
Company by virtue of any fiduciary, advisory or agency relationship; (d) it has been advised that the Agent is acting, in respect of
the transactions contemplated by this Agreement, solely for the benefit of the Agent, and not on behalf of the Company; and (e) it waives
to the fullest extent permitted by law, any claims it may have against the Agent for breach of fiduciary duty or alleged breach of fiduciary
duty in respect of any of the transactions contemplated by this Agreement and agrees that the Agent shall have no liability (whether
direct or indirect) to the Company in respect of such a fiduciary duty claim on behalf of or in right of the Company, including stockholders,
employees or creditors of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
<B><I>Governing Law</I></B>. This Agreement shall be governed by and construed in accordance with the laws of the State of New York,
including Section 5-1401 of the General Obligations Law of the State of New York, but otherwise without regard to conflict of laws rules
that would apply the laws of any other jurisdiction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
<B><I>Counterparts</I></B>. This Agreement may be executed in one or more counterparts and, if executed in more than one counterpart,
the executed counterparts shall each be deemed to be an original and all such counterparts shall together constitute one and the same
instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
<B><I>Adjustments for Stock Splits</I></B>. The parties acknowledge and agree that all share-related numbers contained in this Agreement
shall be adjusted to take into account any stock split, stock dividend or similar event effected with respect to the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
<B><I>Entire Agreement; Amendment; Severability; Headings</I></B>. This Agreement (including all schedules and exhibits attached hereto
and transaction notices issued pursuant hereto) constitutes the entire agreement and supersedes all other prior and contemporaneous agreements
and undertakings, both written and oral, among the parties hereto with regard to the subject matter hereof. Neither this Agreement nor
any term hereof may be amended except pursuant to a written instrument executed by the Company and the Agent. In the event that any one
or more of the provisions contained herein, or the application thereof in any circumstance, is held invalid, illegal or unenforceable
as written by a court of competent jurisdiction, then such provision shall be given full force and effect to the fullest possible extent
that it is valid, legal and enforceable, and the remainder of the terms and provisions herein shall be construed as if such invalid,
illegal or unenforceable term or provision was not contained herein, but only to the extent that giving effect to such provision and
the remainder of the terms and provisions hereof shall be in accordance with the intent of the parties as reflected in this Agreement.
The section headings used in this Agreement are for convenience only and shall not affect the construction hereof.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.
<B><I>Waiver of Jury Trial</I></B>. Each of the Company and the Agent hereby waives any right it may have to a trial by jury in respect
of any claim based upon or arising out of this Agreement or the transactions contemplated hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Please
sign and return to the Company the enclosed duplicates of this letter whereupon this letter will become a binding agreement between the
Company and the Agent in accordance with its terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRxADE
    HEALTH, INC.</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 5%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 44%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Suren Ajjarapu</I></FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Suren
    Ajjarapu</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confirmed
    as of the date first</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">above
    mentioned.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EF
    HUTTON, division of Benchmark Investments, LLC</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:
    </FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sam Fleischman</I></Font></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Sam Fleischman</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:
    </FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify">Supervisory Principal</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    </TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="text-align: center; width: 100%"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></P>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>ex5-1.htm
<DESCRIPTION>LEGAL OPINION
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
5.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>The
McGeary Law Firm, P.C.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1600
Airport Fwy., Suite 300</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Bedford,
Texas 76022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(817)-282-5885
phone</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(817)-282-5886
fax</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">August
6,</FONT><FONT STYLE="font: 10pt Times New Roman, Times, Serif"> 2021</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Board
of Directors</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">TRxADE
HEALTH, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3840
Land O&rsquo; Lakes Blvd</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Land
O&rsquo; Lakes, Florida 34639</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Re:
    </B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRxADE
    HEALTH, INC. <I>formerly</I> Trxade Group, Inc.</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registration
    Statement on Form S-3</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-align: justify; text-indent: -0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ladies
and Gentlemen:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
have acted as special counsel to TRxADE HEALTH, INC., <I>formerly</I> Trxade Group, Inc., a Delaware corporation (the &ldquo;<U>Company</U>&rdquo;),
in connection with the Equity Distribution Agreement, dated August 6, 2021 (the &ldquo;<U>Agreement</U>&rdquo;), by and among
EF Hutton, division of Benchmark Investments, LLC, as sales agent, and the Company, pursuant to which the Company may issue and sell
up to an aggregate of $9,000,000 of shares of common stock, par value $0.00001 per share (the &ldquo;<U>Shares</U>&rdquo;). The Shares
are being offered and sold pursuant to the Company&rsquo;s shelf registration statement on Form S-3 (Registration No. 333-248473), initially
filed by the Company with the Securities and Exchange Commission (the &ldquo;<U>Commission</U>&rdquo;) on August 28, 2020, and
declared effective on September 3, 2020 (the &ldquo;<U>Registration Statement</U>&rdquo;), in accordance with the provisions of
the Securities Act of 1933, as amended, and the rules and regulations of the Commission promulgated thereunder (collectively, the &ldquo;<U>Act</U>&rdquo;),
relating to the issuance and sale of the Shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
purposes of rendering this opinion, I have examined originals or copies (certified or otherwise identified to our satisfaction) of (i)
the Registration Statement, including the prospectus contained therein (the &ldquo;<U>Base Prospectus</U>&rdquo;); (ii) the prospectus
supplement, dated August 6, 2021, in the form to be filed with the Commission pursuant to Rule 424(b) under the Act (the &ldquo;<U>Prospectus
Supplement,</U>&rdquo; together with the Base Prospectus and the documents incorporated and deemed to be incorporated by reference therein,
herein collectively referred to as the &ldquo;<U>Prospectus</U>&rdquo;); (iii) the Second Amended and Restated Certificate of Incorporation
of the Company, as amended to date (&ldquo;<U>Certificate of Incorporation</U>&rdquo;); (iv) the Amended and Restated Bylaws of the Company
(&ldquo;<U>Bylaws</U>&rdquo;); and (v) records of proceedings of the Board of Directors, or committees thereof. I have also examined
such other certificates of public officials, such other certificates of officers of the Company and such other records, agreements, documents
and instruments as I have deemed relevant and necessary as a basis for the opinions hereafter set forth. In rendering such opinion, I
have relied as to factual matters upon the representations, warranties and other statements made in the Agreement without having independently
verified such factual matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
delivering this opinion, I have assumed the genuineness of all signatures, the legal capacity of natural persons, the authenticity of
all documents submitted to us as originals, the conformity to originals of all documents submitted to us as certified, photostatic or
conformed copies, the authenticity of originals of all such latter documents, and the accuracy and completeness of all records, information
and statements submitted to us by officers and representatives of the Company. In making our examination of documents executed by parties
other than the Company, I have assumed that such parties had the power, corporate or other, to enter into and perform all obligations
thereunder and have also assumed the due authorization of all requisite action, corporate or other, and execution and delivery by such
parties of such documents and the validity and binding effect thereof with respect to such parties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
McGeary Law Firm, P.C.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Page
2 of 2</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Subject
to the foregoing and the other matters set forth herein, it is our opinion that, as of the date hereof, the Shares has been duly authorized,
and when the Shares are issued and paid for in accordance with the terms and conditions of the Agreement, the Shares will be validly
issued, fully paid and non-assessable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
in connection with our opinions expressed above, I have assumed that, (i) at or prior to the time of the delivery of any of the Shares,
there will not have occurred any change in the law or the facts affecting the validity of the Shares, (ii) at the time of the offer,
issuance and sale of any Shares, no stop order suspending the Registration Statement&rsquo;s effectiveness will have been issued and
remain in effect, (iii) no future amendments will be made to the company&rsquo;s Certificate of Incorporation that would be in conflict
with or inconsistent with the Company&rsquo;s right and ability to issue the Shares, and (iv) all purchasers of the Shares will timely
pay in full to the Company all amounts they have agreed to pay to purchase such Shares, as approved by the Board of Directors of the
Company or a duly authorized committee thereof, and that the purchase price of any Shares will not be less than the par value thereof.
In rendering the foregoing opinion, I have also assumed that: (i) the Company will issue and deliver the Shares in the manner contemplated
by the Registration Statement and the Prospectus; and (ii) the Shares will be issued in compliance with applicable federal and state
securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
express no opinion regarding the effectiveness of any waiver or stay, extension or of unknown future rights. Further, I express no opinion
regarding the effect of provisions relating to indemnification, exculpation or contribution to the extent such provisions may be held
unenforceable as contrary to federal or state securities laws or public policy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
opinion herein is limited to the General Corporation Law of the State of Delaware and the federal laws of the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is for your benefit in connection with the Registration Statement and may be relied upon by you and by persons entitled to rely
upon it pursuant to the applicable provisions of the Act. I consent to the use of this opinion as an exhibit to the Current Report on
Form 8-K to be filed by the Company and further consent to all references to us in the Prospectus Supplement under &ldquo;<U>Legal Matters</U>&rdquo;.
In giving such consent, I do not thereby admit that I am in the category of persons whose consent is required under Section 7 of the
Act or the rules and regulations of the Commission thereunder.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
opinion is intended solely for use in connection with the offer and sale of the Shares pursuant to the Registration Statement and is
not to be relied upon for any other purpose or delivered to or relied upon by any other person without our prior written consent. This
opinion is rendered as of the date hereof and based solely on our understanding of facts in existence as of such date after the examination
described in this opinion. I assume no obligation to advise you of any fact, circumstance, event or change in the law or the facts that
may hereafter be brought to our attention whether or not such occurrence would affect or modify the opinions expressed herein.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    The McGeary Law Firm, P.C.</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    McGeary Law Firm, P.C.</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>4
<FILENAME>meds-20210806.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaWIKbP9z5Z8WekhvWB9banqny8t3BJUIysTLV22kTUN -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:MEDS="http://trxadehealth.com/20210806" elementFormDefault="qualified" targetNamespace="http://trxadehealth.com/20210806">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://trxadehealth.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="meds-20210806_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="meds-20210806_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>5
<FILENAME>meds-20210806_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>6
<FILENAME>meds-20210806_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.9a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://trxadehealth.com/role/Cover" xlink:href="meds-20210806.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://trxadehealth.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>7
<FILENAME>form8-k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="meds-20210806.xsd" xlink:type="simple"/>
    <context id="From2021-08-06to2021-08-06">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001382574</identifier>
        </entity>
        <period>
            <startDate>2021-08-06</startDate>
            <endDate>2021-08-06</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2021-08-06to2021-08-06">0001382574</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2021-08-06to2021-08-06">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2021-08-06to2021-08-06">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2021-08-06to2021-08-06">2021-08-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2021-08-06to2021-08-06">TRxADE HEALTH, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2021-08-06to2021-08-06">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2021-08-06to2021-08-06">001-39199</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2021-08-06to2021-08-06">46-3673928</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2021-08-06to2021-08-06">3840 Land O&#x2019; Lakes Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="From2021-08-06to2021-08-06">Land O&#x2019; Lakes</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2021-08-06to2021-08-06">FL</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2021-08-06to2021-08-06">34639</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2021-08-06to2021-08-06">800</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2021-08-06to2021-08-06">261-0281</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2021-08-06to2021-08-06">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2021-08-06to2021-08-06">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2021-08-06to2021-08-06">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2021-08-06to2021-08-06">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2021-08-06to2021-08-06">Common                                             Stock,</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2021-08-06to2021-08-06">MEDS</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2021-08-06to2021-08-06">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2021-08-06to2021-08-06">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2021-08-06to2021-08-06">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139893939662664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Aug. 06, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Aug.  06,  2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TRxADE
HEALTH, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001382574<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">46-3673928<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3840
Land O&#8217; Lakes Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Land
O&#8217; Lakes<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">FL<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">34639<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">800<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">261-0281<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common
                                            Stock,<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MEDS<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Elected Not To Use the Extended Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MW&,EC'%BM/XU@LD/['X 4$L#!!0    ( $>+!E.JQ"(6,P$  "("   /
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M              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL4$L! A0#%
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M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( $>+!E,D'INBK0   /@!   :
M          "  <@1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( $>+!E-ED'F2&0$  ,\#   3              "  :T2  !;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  /<3      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>96</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="form8-k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://trxadehealth.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="form8-k.htm">form8-k.htm</File>
    <File>ex1-1.htm</File>
    <File>ex5-1.htm</File>
    <File>meds-20210806.xsd</File>
    <File>meds-20210806_lab.xml</File>
    <File>meds-20210806_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>14
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "form8-k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "form8-k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "meds-20210806_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "meds-20210806_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "meds-20210806.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 96,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "MEDS",
   "nsuri": "http://trxadehealth.com/20210806",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-08-06to2021-08-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "role": "http://trxadehealth.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "form8-k.htm",
      "contextRef": "From2021-08-06to2021-08-06",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r9",
      "r11",
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r11"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://trxadehealth.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r10": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r11": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r12": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r13": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r14": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r15": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r16": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "Section",
   "Publisher": "SEC",
   "Section": "12"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>15
<FILENAME>0001493152-21-018929-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-21-018929-xbrl.zip
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ML]X1J1;\<+37O2+[]0XOUH#^WN->C4>'B_6% J(_H'U;1P#AUQX0[DM)X"2
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M(SM-/ VZZU(5TP0/&H\&GD3^PAPN%GQTN?F,4WA0L?=L*I-/5YU8_E;=R&7
M.RH$T<AF([>Q5FYCS-S&V+F--W112K&I*UV)1;G&=4JGL $EO1F9^L<2W#&X
M;)^4.MB#7]14X+#V")T[E':IK83DE@4^GZ)%+0(9;2B\+\T'?SI[__KL[ZZ2
M[\>L_H@P5!/KKA:,N_$I_X4OP>R#L[2>HV]!J%BTV3/&\9:5)'*PE!%6EC0B
M27_L3LV:AJ9#<7<ZI#@,#EGQ=,ST2ZF7L>]RFM"3Z\V,KQ04HA0V?D3/5HY.
M=/10K<M+#Q?EGDT%+PJAA2H7O,-30L(:O7PE__M\Z(%Z]=X)B*,1"*?CLK%*
M W:[H&ND<&"_!"NF [M% R$-G-[GE-L\FM2HQP;RY1+"*BG9%@9XFTAU7;*#
MO"5=&X028JR+KO(*3+VB6C=D$X(,J*92KAPMI%:GU%=2!W73'EUI6LO'37H&
M-/9X$%-7E!.R4 _W%;7+HKA]3CMC"\9.!T8UJB_)^)2QC4>1P44X&C7:%JZ$
M;R'JSA</MI<KQ3.[Q'9+'S>)1@*IP(;B@NP@<<_S3DV>5BM=\<)\[VIOWH)_
M!DNTT2I9O#]G"G-(X<^SXZ[7^O:G=SV_=9 S6IMS\]DR)5>=TVCY+1^P--Z>
M)7U^R)+>:9;T^2%+>C FQ)@H[C(.6^<<YHK:'R!KZVG1UI:()&J)4(!-HC6H
MQU'V$\:G$],1+I-U@9FUPOY%7B0&2"P-@OP!0O PE 9C/V![%LWIXUNGQ@HV
MX]4=T3#<46(C<=(])0S%2<R*;?<=82O'#Q#,Y7I'Y6S'BQZ/0C=:<;9'W ;=
M/<6[-":417%.-T(&8=TBU8W]C/M68\MD <ZT[&#=9!]M^: SXHZ3W?P4<*!I
M\<RQQ.K*@1/'6XJ)Z+STI9<Z@P>LQ+_,J4P^%5*DA15$1".%&TUHN8POJE#G
MY@-,P[[R=(CU]J;"E!F1.GA)S]>2O'_T?YT]+J1-S/6E+T049>6&P\A7/RG!
M;^A/T?D%?.NWIY^UC+@H_Y8;"C)2AQHAJ6:>W,B$2=JYZ"/R!.]BRMZ#Y<:U
M \#0IF%$#CJD=[A_@[&)$8^4SRQW@F6-+Z8-\%O!Y)DC6F415HQGAWXBI.4N
MD :@P\LM7]O"S6W54I>FFX\(=<(2FBTE->$=<I0LW4-$+MX^I^@S.(S%)2:L
M@FB97#B5J9D,KR(Q-) N!?%!X2]LX$F*QM0?9BV[6I::+% WF&B\HB/AFP/(
M[O B:6.6X?L$#J<NA3UBY^0K8ZAR!4JQ50^:1X'T4V;Y?>?QS[BV=;Y8JIKE
MZZ?WR1]&>J\9I"P)G'8\+A5;2:!PP8)#SR4F 9/L$EFB#CF@^S:5R2=7?HSY
M^(9\3S2D.;;Q2$\R'JQ+BHN[7X'4R3Z'=;S.I;V(<$/ "(ETBB*43;6N,7'3
MM[R-%2E9:^)>!3D,(G>*8/4K1S"/U! 2RLNP@(],XE@(W@7>\ ^NI8G&3^7
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M#+%$\')W2!L$S;14'H#XDJQF7]C5X>]PFIK*;.S^/M,'*@TP]5BJD1@=WCB
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M*^U%QY0ZI6>IS>9\ :5I$OC7%(%K>=1'G+46(B,3AB$:3Q[B!&/#SL2'WWH
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MK)105;>.5PU1,M#(.*%209;*K2:(@D])*[_$DRR&@VKLJ(@K(C(UMI7U>-^
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M'?[<\O-/AI2K<6&!\ZIRQTZ!>I<I>T[MNF;/3,\9AH@S;-Z$T@*N)_B$ =E
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MPM07%<91!XK+"M=3R_U-;3UL$&4HEU*S)EPMF1H08=[648:9AFJY0BP)?>;
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MF\&S6DI/^*B%.F(=?["2[J99<E54_GVF</;'6&*C5S0BPQIXR'CT8Z2AK$#
M*9VU6,#DZH;C"])HRP#+G5BS.^RXR[0,$R[_5&J%/I;5-440+)7#>.3&=[B_
M]V@BD^5 2),30;1_RX*N2.OS40L<3>T\#OCMM*X^FM\L<G9@\("Z7YJFJWU_
MFB^,5YU]T$80$!$?Q"%;S&7=CHK1GD#T3Q?"Z9 AC4>2QGL ._QPCNHE'-77
M-R2.BG R,">UX5R<9DW11&&K)N!-".6YQKZ0J7Y%I52VY&@;^=?A*-VCB4S*
MB-5R">J+55CJ[1;]9>H*)-NZ6O+N4FIQOA8;5_/;F@DRS</@%TW()R_@^F8\
M>G+RF![V]<ES0MUG]30K\^;1SY^6N6=;-V>]-BSS;4!Z[^.JSGK*03S60D5L
M =&63 89IS1/T$,@..8N/NW*TXIW2.BIIY=$YQOGO"*&%:1SSZEE!H&O\)\D
MM+DS)TZ1'X]R-\X\T2B.Q@>G_"UU^J5V]PXGNF-3TJ&]=.M' ;;]%C#Y_=9O
M/,IFL_7EFC68-L98ET6 FNS& .$2"###K@*^R/4&-2U1Q01DJ%GP&0<-I(ZF
M^"'-L31X_@0=1>!/P74NUJ5V&^7R T<:A\%:;@?"8G<..\K5)MS_ I_BEE46
M=(TIGG ;D'E7*KW##?%A?M^UB2$B:)&6LE27U!40+T[C:4[P>N92BW40U/=H
M(I,*!/7_^U83EX2B^YG# \?_WP.8WVV"O4\.P=Z[#?8^.01[#Y)FL@))\R8C
M+$2@P5$I*E6!8)H3U_:--%*:E'DA84W_O3(@S&0#<YY;RU( &!P[-?I+0 H<
M)2*+P9&U:*=07Y[(^-1D@8/1!B8^Q)MJC#=#NV:A7"Z.E'Z8EHWI6]R[/1C%
MCD('<9NWGSS;\G9C7E&[Q6&N-A-/WH-8)PRHN0WUAAGN4TM$!',.8+CV!.-1
M(;RG]'<I9MA)N)(U=[59Y)6,1QS)1.H^L0<M[_4@D9_;<>-)2/9\CP(, _PF
MVXWSX+(#VL[I@IL:\,:EB/-58!E9^.@%)!_S'$LK#C;6/9K(Y)\@^7XN _!@
MK.Y%LCB^MXV5=E07AN4Y_:9%P\">'I!@/)J8^VPS8I[_$!]A"1"/7G 8G5TJ
M% -<9%WW"JC_:\#+>B$ *7F"?!,\'EM[/>"@F6YKKK@\6E#U@N/]5]W7V#+D
MR$N(]-2^1=CF!PJ=J7K=H3]IJRS/JM9T-5YT<WG[2XRJS=%+>@W?Z1:WIXY*
MLL?(B>+TQ]G?<@36_)!=@\$"4_GE^-5QVJ/Y<-A&4[H4<(.@ZZD 6.4'QY-7
M8L$'=TX"^5D3%F>9P\>83Q-G+^P<4R;JHF4GA]=1!#&\&[_3&'PWO.#;7[\[
M*\O\4W*&/0\3KB [3O[1X\()FB2.1T_@VDB7Q#(!6;RF9H,<?"1_F&"5/ NZ
M$SQB+B0)E[L)2,2JX"(&C9IB97V& M;%J'C=B49$UCD[=S4:F8PDF73.P#MM
M+/,#_;W'<*#\++J@( $<7PG&0Y7,-A,LLZ-XU[GK\F"C!0\Q#CI/\IHZ\B$X
M[,H' V>VP(05]\Z9<_"C W<>CW1JEMC)PP(+UTK4CL^5@WC"53+&7.''WK!$
MNEA\/XE@(NPWZ+9/A]Q9\(?;KN?+['C\BU0@@?2[J*[S*^TL:DPK NSQQ_Q=
MQW.AEWW'.2\:S4E=9Y1.U01;*""8"++F;L&M)"X0=B+\+U7RP8 >?^*4;('A
MN5)JEIE9."/2<.VQ)=1J:_CODF]V5H,@(VX0>F%P7JT"D'N,L<G8F\.VHER(
M\ZGUD^C,[CC9 1XL0H?,"TL)(LX)3LVE!)Z)3*DWL^YB7F/+C#9P \B6UGR/
M+!,E((NY=+/E/3[S8C2VW9X&+[[?3,&2<)0@NJ+TR\B2PK&0>@V88V-@0]%>
MSEM4\Y#NS;9JWJ2K>","N#-R@H3"T/\4H7;H?CYH[-<W,O;#JQ,K0!7^2#Q(
M2#TE\&9M(SS/40;14PWQ 9-.98@TV3@8LV>!T^X&P0%%VB%GNF3S>4V9)/R,
M?'' $C2O<A].)B1ABEHI]\6:9#,W,(K>$D<A,I9?HLDX8!NEVB>0I1?[1AO*
MQMDU4*8KLQ11Z%VT2H5B3O3 *'-_D"$TOK_-B^#G.B2:"-$QPS$-#!\_.CGE
M=HN6R?__FO"8:]HL!!^NZ3TLQFRY;IQX1+@(D6=19ZH"?P$;%:.;C'HUS&W!
M1TIM>,+H;\R16*_F?@#Q71/[E[)RWF4R0:Z+[ I+0XB$0%IRRM[( RGN89]X
MD5&O)/H.\M.73HO,F8*>[+[+:LZYRVX'K]#.#"KWG"7K6E2KRY.-1P.^V_9#
M>H_,RWU>=KODR--#<N1NDR-/#\F1+]!J^+.=(6MT=T3FD(E<W\@E LWDW(D_
MT24BA1!:\'^"2S0>Q7RBY ]VB= ;O.6NWZ5CM(W+\G.-U60_6]6L0\]BV.DX
M)0>_Z3[Z34W';]+FJ%$WB>AF7+*D=[NP-6X\63()TIE!<ZN@L]IXQ!E16PEK
M.E --WAS[@ 8-ABQE7/K2BS1_/3?Z!3KB" YVA:$QAF9B&A0U338IRT%]Z&8
M?11TF9GV=,T<4,.I((RZ*P?;>-1IEKD]@-MO#-9UEAQ+X,L;Y)?8>PNR1(9P
M#_???>$O9['4CN]D,D1F:[J=]'K=*4T29FGYD+C785'W*Y^ \@FK_EP&$UX#
M4_G[]JG@4#YK+DDXE;]3K_O):S\9 6;'LFI^7$/#X.Q_LZ7+VFZ& G.,7!9.
MI04Q#'%#;")]&(]PZ%F]9W;NO;\0T?1<1-,-!/EFZ%60]Y_[( J%8$2E"718
M4*RSBR)?# !%@X_X9=6/A"B:-)(]^N8!J(4'U<%*,/$.%2,A(L/>8=HP! #G
M,'Z()APV#V*P,K<7&FS(SGD]AD9)D*MQ#12MB62.KF\K;/'[#A2SN_D[!<QT
MP$)02V8>!6GD XY&OB$H  &C06 *XEN@SPP3,E\FM>(XUK=,XF&<F@=U ? &
M_(0=Q:J5--5VW@'_:-BRO##;DIP/C0VB6J$3Y-EKH[2VE#SN!6N'>NV0V5:[
M6E.IR#1A3=2BQ"'J&U(/47N4E9TDC4.^K7,V#_FL9MK!%_'Z<MR5&(CX?I>5
M:0!$395X4LK?XK_DRGJIQ:I<NRDRI?)(B]H7I2*?55@5Z"LV3.=MUW6)RW<I
M D[9BFDUWSR,\_ZPKJYJ+X7-DI &)X>"&'1NV&US(?[Y>LG@WBL8ZQS_O6XO
M*JY)ZA3Q* >V,PZU4+U3!40U[WI2<_? S%.24\[&MKHW%[HS3CG<;G24UD+C
MJN H#[WL86S?;0+]SPZ!_KL-]#\[!/H/HA1%Z15(TO<]0*+IR\ >+>/9A'+3
M^-*@7CD3NA\7[G8K(6SFYN%U2=B-34T&0\CH[#3+!N#+-%O7-;WC13CJ@SIG
MBEX?PE >A()+-PT/O+*:4,\,RB*<*U,:W4]R2@1N[]P2.[)4WLO!.*R%Q SQ
MK$(>:EQFI8Q-R22;Y[-E5K/K05TY*%)>8#Q>8HI2:K+I=;_$WWTLRGDO^X[N
MC3#@,3V<<[+JW"T,:22*L4M$R+6S-U_4';6D@8X<4FD@0YI(&W)4BSM"B==[
M58@7[_1#)@O]$[9!;1P5R5;J2F*+Z=-4NC.S-0;D;/;P:.-O[$*8F89TGW?&
MXS<>[4GDUX]_'CEJ0G=(PWUNP)YI'S'W7DT]5_F'>3XE:JL@Y",]UC;)C_JP
MLSFF<O+D#0>!Y,^VI;7Q6D*FGV7Q4<+5GJHW&WSRQ#?+&8_PX&9UT0@@?,<-
MBZP![#X%LO$F(8/1@HAG%\L*Z25R<.@NP$_#/V0S:1[A#C'H=9##+2Y&IW\/
MM0-A4[,H!5R7]MCW92U?X%U\$.KE(6E*5)1O''\,>8ONREE0^+Y<[SL4'(MB
M82UU>>R*8&LL00+FI3#Z*LUU66=8]]<2;V$!02$!+-=Y%Y[M.51-97W&Y+::
MM,6;AA39)5\J>LHYGO$2QX_!?5"),^3Y8J^H)1X>]*;=A<OJ:8%2"IUX2<_O
M*PF,E!F/0F'P, [;'WAO[G+8JYO"1FR"8@@ST-P0/%\G/H$R'H6 ^C\+/!)6
M5'W1X)%@?6^+)Z%675V,_4V.PUU!2+A=^3"$9.<P[Q? XPN50;\SF*,%S7UF
M&U>1 '!9FPBFPT,Z.F<]#14MW*VFZC?$T.RJBHKY&A'=V!H"N9=@ZA1K:7(!
M5$>Q[.DV*!)+I+!KK4WD7?G,G><&\O12'N_D<F\RI7N$&CX<W,DZRDCLNGP4
MG*;<@E!1BJ<N]J,)P1^D9-:74T[DBPZ@:+I#,'A80:Q?#%^+G_+6]4CJN+GN
M[&':-B\;=DXIFM&)OO?Z7&=+=Y@5[+>E=\;A -^CB9#/U#_ EF6-W1R,O*!I
MAKEX>H?/?>!W:CX!06,$8T<N.I&7E"DW) BTPI.QXHIR;>6"Y'!"B&OS0&L\
MW=(6I=-I1H7II^)R?>G[$O:OC7G>0ENKH+278_ZRRNHYF#^=:!#&59I(AX-^
MOTC,R!94Z>/4&>4^\\6".><J@WL-TF/8]C.7!!E<UK/WK\_^/AZ]D@C;C]2$
M0<* E6-"E&(4[A@:(RB>5=4JIRP9W5R!'L%#(@,U8Y2^/3Q [3D,IMNY:]LX
M6X)%[3-HOI62;:4C%,R"5'G]X=6#O?\[$F3/#PFRNTV0/3\DR X*;'*-KH-I
M_K"S)TV$@3B;7Q5:A\"=OT*V]:)5@O6F1[#>^"@?F>K=<D;XX"*;!9'T;-ER
MW#GCZ#CW'J(J[S2$U6EYK2NW5&BU:<=J :5!+R+KE*-'_F %[Y<XD<DGSNK^
M)D9TMX2X0ZC=HP\S30F&D.'"31L^UC_2MC9;9M>=X JRRC%=E#U?;9W-3=JF
MU^#.?=)3T8._+MZL,@%;#U=MO-FRX(*!2:2<&HT8,W <[%$B?%=$2</APB;P
M1!R*AR)]!W?DBYC(9 .WXNTBV9D_D2/*>&!#(%645NP]G60<FH9#![_&2ASZ
MT37N,/ S#QEF\WL\,D?NO;=M^[P+I$*8-%(@!4S'G%Q?5)2I)V3SO)<Y]S S
MLN [[W#]D7U)8]8H\D,RZEGIW^L>C7;AK.C&NOB;U+*%,C4+<D#,UXAT.S/]
MNGEXA^MQCR8R^5>TZ,W'0G?3@\3K4(A@ ?WD<K8)+1".GC.V*.!1@/L1(?T(
MRU5 Q=1YF]7=UCR'0W6OBD*?'L/(J;#IE2NQP!T+-?G/'EZE!4\<;3"X*]UG
MX=CU>;(ZQ[BY&CO:ZPF9].MLMJ'^R=TRD_T*.G%JW*<!Q/3$=C9+.Z4L[O0>
MI3'3*"4SHU-K@S 17VGC6(:=&=:QF*3ADD+97)-@J4VQ42;7^TF:/IDU#-.+
M J7FE*'+^<UYF[*EJ8KY4^JW#A7*@\(Z8UM&Z'CEM%AT2:_<)*RU;9G[TGUN
M'UY@T_S&>07@9W3Z:[,)'FV+$],99"1QO6<'2C-18V%@#D>)?L -?CP:8F:.
ML4DK%5-6EG(?X@U)-,E',Y]H=Y%:"1VKTE9C3[XZ(BP<_>KT.?[JZ,4V8!XO
M [A?F2,P+:[R%PA,,+5)MR]&<L@\6XW$1BX/^_EC+"+?TO\W6K;4+1]*=E8/
MA?#>6Y8/V5-CBHA>A 5$32\IX$R,K,0%F3LHAZ6!0MHGX0+W&*H7#M,EB=X^
M*1:#4;S8#$AZ.;;=Y9@:9'7= T6=[KE4"DQ$)O>CWG1=!25?C<HD^9Q:=CGH
M0R>_^S41N+&<6A,P2^AS<L@Q+)IU)-Y#%WVO@Q?1*@@I^ARU(J8-L2VL2ZHE
M]B2^<-4HP$F(AU0O3R<*)-'-\8A: #$PD+E>J-L29I&IN"_;_UF)>12GT9MN
M_9= 0%LIY*=DGR=\HR I=7T@7\4Q@[O/HYD:(\4;+M9L$Q WRSQS-/MD L:>
MT=U&OMJW*M8DOFMT[+6FN:C!EV.,BC((.L3HAOF:T2CN#OC!2H\=B;F_'A)S
M=YN8^^LA,7=0?Y-9B,;W'/\AWOWS /I]HOY(71S%%;84QK6QVK..OHZ6H"4W
MKD C2W_?$K3?K[(,*:EMA9BO+(N%QBFZ,5Q?YBR)6Q68T8KL7V&6_%X%9M)=
MZ0859A&^JKLH, ,;Z8859LGO4F F'=-O4F&F#[M=@=DTMY4EKJP$6UG<J,(L
M^7T*S,:CFU68)9]38)::$((KZTUI5S+IX$Y!3K/UV11>,& S_[:>G[.-BO9N
M@X"&XG)5HZ29(4<4LBV21Z)]J#BM5-6>3]$EK!ZLF?@E3F0RC^(W279[1B2E
M/^M&FMDWB#1&..SQ/9K()+_C/:X/>WS?)C)9W/$>-X<]OF\3F9S#'G__]J=W
M9W9WZXSB@"7H7,J/$OVE-%_(BIJ2!]RP44':-I] .Z^=*QFBSGTI:K3B*)QU
M. /W:"*3"X2K(@Z#LH+QI)>+8DXW+FTUS"",1*7.5>,LG=B27411)[V C=OG
MN4VHV5ZD)K>&*7$Q,ATZ2+*:9H2'<W:/)N+(0V.97(8 &=R.J_T*O09M7,A)
M.9\[<_S. 5J9)4].H8E9+F"U#1ZRC4@Z[]RY>LS#H;E'$YG\AH=F"\0WBIOD
M]'*W;"D)JY88*:1UBYTTIY0]D>)RM5E"VR>CV?;LD-V5NTCU )N>4E;*==U!
M=5EGX:3J2<DXU%X+-^62:,4OGG:M]ZUJQN=@=R4.Q1"F,^L4 JLNCR_< SA7
M#^:"G&$SOZ"1;"@!4]=GLE^QT3!.>#K8,(R.6>,08!A#+4%4,CG$1LC)58+"
M,.QACO=:VT^\1RH8%21J.!6DDVTIGL@,%B#GP/JMUR-K@M1X7ST\V+._(R'Y
MU2$A>;<)R:\."<DO4'C?.;3TF<,YOX577):>R1O%TROXN.;/',#Y0<S[P>A?
M@M1:;45H;,H8%K*CS&-Q45'WR/IRB;&2T&BSO4!8);G3 (KMEZPFSWJ285IM
M07CN:;ZLKH_$>",,.(*A6D[%8*X(QSQ;9L4EIGVS2[C*F+VUR6 PD;,E/CAU
MN1C$"%YG]1RUI$\C8YJTP;_EGY"%0[RJ>=%,,6^EWY,$^?_?WK4UMVTDZW=5
MZ3^@4F>WI"K$UC6)[=VMR+>U3RFV*]8Y>_81(D$),0AP 8*V_OV9OLWT#(84
M[<B.R.#!5;)$ CVWGNZON[]F'FPCB-BN'79%4$F6:*96"W.;6K2PJ%PT6!60
M:&+M,K_BI"H.:MTF$T:FKHH%P5#F9<9I0$(Y-B7@]^[F9PF@Q!!3O[K+66TF
MR,N&5(UMTD02>LMB6E!J/@7((G(!?X\_6=PQXYK:B&*T+:6^179:X!W&))]E
M#?T(@5I.F#6;@+-G;>!-D_.EFIH/XVAJKG=WPK DVGY5Q3@?6E:P[E><D5"Q
M%P&O"G>E)OG;WT_VX#ZF1(?R)O7[TYSCGNRUI8&I@9R$\H8DE?^EQ$<!N%&J
M6RZER64&O^YFV%26(ZK,S)'2,WK#"8NM^ZL(Q+UN&9GMD',!"0#S"M<B[T!6
MD!&DEMAT@Z97:($S7GWO_:H'G;L.X;D6&H2""]\L1;]>@_*,=9V(S7* J:P7
M9BMS@PG;@\45A]CXK/QI#_(SF3,1U$K3D0RVU-M[D%L>2>/T^S\1JZ/[ D6W
M,9@,MON(VWCI">99H>R+Z(3P(]K<JEFY.)W3D@K9LS06^C2W\7U[<FACHB\S
M,=X'M8;!9D6EU8L@7+:[PZ25$^(CPF?]UIDM."YH(^S!<5(U14;1X$'+9K,\
M*_<M+$K) ]":K2G,_54P=;\]"5)FF5PU$/6O\BMA_X)U 7=HTI60)2DL87QU
M](]GF^<?"#GQY\C6\_B>5E:VM;W 8):J.O90ZB!/.<-PW?!5<>,R'ERBD1SI
ME _-O.&3-:^;N:==]T/V)^Q>LL:!)E@&3P+E[*#7MM;B.]&+]I;E3VY9?:-8
M[W+Y4;S>W%M'.;(S$MX8NSMJ9UQ<8\LR?,Q<G4'M^0N,*J7";E)L]K=5-?8J
MG&)Z+XQG:UWBS62!%9A]I6843BTX$Q9$=+5\5"S>AA<Z?,B[U"-6:GC#/U8%
M(BDUR*);2J@7ICF2CI@-AZF7D&5&1B=Q$#;P4PYT66"_4N,X4.R<?(9XSA5B
MFHQYPFW#_;I0W9@18), .R857()^D:H0;I(;C0A9?2Z:A<0.KI>8$X!.:PT_
M@OE3X2\Q$PX,?5]L.Y+=G<^5VRX%7_(DZ135]CHK'#WAKDW!382W&>!B=\Y1
M8[%BZ*FC/^;HWX?6,H\&/.QN\;!' QXVW%[28._UI,<XO]*II7YMTRELF3&Z
MUY:1/JLB%JQY%+2':ZD[]Y0 "4^3PE6UNV.#BP#BS+V0!.:O6XY"(N>"+)@G
MD/,DX3DBG3:_8&)S(:%F$W22%25P6B(G?D1,(QV]VV<"=R%/I,Q>^%36:#TN
MK]]?;A3KAX!;/YIWYCUDFTH:,D1YS/UM#&-S#6)2!V5>\$"LP ^2L]B 5!QS
M[G._(&ND!/?%)_YH?G5=%Q0VLNZM^5L*.->8[^Q\-0HDX2";.2#WHM&>5<A]
M '+?1#Z?!A,&5%00(0;GP[K_9M4GQ,[,#47A0QI$\S@O]70+UB7O'.= 6A)T
M'B3Y^@D42-()N]#Y08KW4FH.  H4E' )EF-3;Z*5 )#1-<<"8&3ABDEBUEXA
M*A1 A#!X\%6/D2-E8:DH90H'J6AS)S-B!<S[F0'RE6%E16,?)@MC3"8+A5C'
M#2#  %A,DZY""!97V<U4JE^OG@\5EQP]%^3./,%27$"%#!0?V*>CWTZHH[0_
MAG$( UZ&Q$Q1=YWY2'O/-Z<\A[QZ GO+4GNM#C>U^YQFS59ZCFMB"!2\AR#B
M"1UO+* @8'6LD"YT)OT*G:B"PNT&=<-8]N#J;V/5I:/K#%Q_Z.Z@#TK13L$L
M-N?73$#+K31G'8%8LIY+WBPW!!<+C%9^98MMU<T<"K/(O*Z8JR+@9@8I*#@"
M)4AXRXY4. QI]#/6:Q,"FGQ7R*]L6NDL<0VX>3.P.1?SWX\&W8X%7@O_3R 6
M9:=5V$E- %*4PQ;8F.N.2@0MH;$Y/D![%<G7T#,:CM]_YCSHQR'6CYWT7$XR
M(Z;*Q(K?)MB*1Z: U"AR+#9C/\N$\&/,;:KR";$_([,IW'Z^Z2,93KZC#>DE
MQ;C(&LN()'@"8 9<;56!+UN-G2_?$]E]%E?*?9J,4K/?]C#\1"DP3!=5EK7>
M3LS58;9EA_&B?4OV"I<)NC2V.Y-4DE[>!%22J5T:-%0;B@>W7'@V 40&'X&2
M1&<PQ8V,<*[W=[X]PQ*YSYZBW1T]1U&$5M,70%':O-7QE);WCL5"9<0"QYL/
M0&L9O&^Q-TR^@,/L*0.SZ#D5%+8/L"LWDQS2T26CB$A6S-V9=>.NA&-J)/!#
M)<Z.0O"II+0ZK6PDSNK1*/(ZXB3K-Y(9MNJ%9#NMV/9[>+T9O[R8$5M$396(
M].?]6._AWJF@GCU+CH4;\ACP8'E##LW$Y9@[NGIOJH&1$2<6;VJ0B.CDV6R>
ML2'C[0DVDN&IJIPXH61*UWK3:R-VYL>7\M9-F @X%;I6< *<PZ*TAQ>S@P".
MOTM1XA42W=XFJ8(0";5.IRE5@CG-26?<_%4=J-T=L?G )6/:E6!(P(Q4U%V[
M=%!A^>X?3"&[1=;.5R7>P>#+;>DAX>E6I]>%BVI.9.0,$D2G0Q9 4%9,@HFJ
M>TDEMGT,Z3@RL"HL&JX%DO8EBR/I4O!U>&IICWM<;^]%+QP=R(<\GNB]7JA!
MWKE&R*&7%8.:.[1:/%.'X]$K7L+VC+'VK$V3+B^ 69(U@K=<SS=WV18I6AF!
M8PH7#55=6]8M\\)5/O4^**:VGF0-TEQ@H#.>$H3^GR*,P(MGQ&D(_:2<?<RX
MR"7?HB8639>1$2=C4ED4\(W2.)S(!;CJ<V#;NZ[*2,#4RU=8QGD$<_HEE%01
MHL,>Y=%2JL  (4J5@1\;Z7JSX#YG?_<Q(T\%E^<;S<(MO%R:H8\0"<XCYRTQ
M9F, @GT8<H(]+/M7LY]X54#Z/)H[CQ0G.SHE)0=TK67_H$PI=J L%E. $P7K
MA ?5F$<UEW0P^[7 GF321R7QKEN&_6RIH_Z*8CV@,X<KI I@3X'FT7@2! ('
M)EPLHTCG@@5I7TJOV>.="O1#9]NE\)%^&^CX[J&!8VOB[/Z"PIS6.F#6!AA9
MWGEI.VXWH6;=KFIO3P+3.]5@VOT,^7Q2FUO[ER !?X  YL:4G?C$R7"^$3HH
M^?#AI:8)47^'(OH<-:NX=O10LTNXE+2Y[S-GJI>I[HSN K]FACPV.MZ52&2_
MN_-<41BQ@;'%MO7JJ/?QP1#UOM.H]_'!$/7>Q&O@*]#2O1:+(H)1CZ4M8)6$
MK8U/I<UU5V6+K"@%F0$Z)]L,$1(//?<2=:=S<:A).^I"[O3,&':&9-G \\Q,
M3@@2HY-HO5=,4E+1W3Y>S* &<L4A9]R-AQCU)0%ZO)!$;4T'IC$V4L-LJP@I
MKA@,0](1H!7"WS/X55-0'VYL3U*R)[0:L/;S)7UDU:]Z].%FF_3[%GBNV.3#
M"%[!;4QC6//EC<::<6"_ V#VQYVH80O<3'!\; *\>>_)M#X<O=:<"?Y\*_+L
M8\YH.?4@Y_6V5AIBTB@! /*W0=.WH;U?OF<$Q=W=\6!<-GFP#U4000 $MH92
M[@J+U+GM;G_O[7&3=+/'NA':8))BL;]4<*QT<6_P>&" OQ"T@"0X3NV:1(%-
MXQ_EF:V?I^?-NDNSA8D&#I5.4XQLH3KSP'E3#;@!["^%=4.HON!N,+AE<RI*
M3D%)P9%CXQ+JE!Q;'KR '?65KKL&+8@TNN9N!RM=>L4T[7];@.^Y;]6C@UY$
M-HYJ=F9W#>/QG,:AMFM1$4YA'0MD#D3PT7\=QKQFL(DZS"''V$@C^?U,WK\<
MZ9!A>@DC+G^'I06'G(YG(=R+' *-Q(&+B1>=B71VUGI_M$_\TG0VO#V 1 J)
M.:>9#N09H3$C2^H)IF87U&-<7O<A A%M<L4<.+M5 SE$@I8HA%!9X@XAC@@;
M)+110V\@-(?Z/J74L=@5VJ,A74_-880QD"Y92[A83$EH)Q#FQ#P32TII4[94
MD;UBGF12@_[(OAPI<3$>RAI@^EW2BA*G[H]M=P=G/A8)4O'V^)RDVH.V:7N7
MMGFB'VG,&8S#Y86V'I]&CE?+'!GZPZ5.VF;5B*HPFZL_,*^)5<* M0'-YUQ2
MY&QHBI4LJU<\*JAC>W^B.%5+.MY%JI ^E?>21=2XVQ*@%!8'1R1"#QQZNZ$B
MA@U@$YC6T;1.K1"V%:A46"T)U5YU13G'S+"5,> E90$VF'&X-]F/QS/VI2#J
M<P/( .7"=G 24C+EJLCQ%K@[V^.W ='IF[RP-@+=+#9SS:]2P\8W2+*2NP\H
MBXO4 [??G=]:V4@G77<!,B<!\TN+12Z@^Z0#YA3((*(;%!].E\@ZE2.7!:DZ
MQ/'#D&3/U"@:172.ZANTEP0HLQ9"D/0SO:"H.&48GL16\:K4R! 37?&9I:*D
M(D>:P*?H"W0D,[_3VF*+685O0?D.!Y3O;E&^PP'EV\#;XLXY3WZP7"^_^BT=
M40N=N2Z.1B>^[YH%*/+GQ'5^X]I;GI6]EI!$)N&:0@: BFHU5'E<6  ;X./!
MN!872D*^\<Z2OG/IOT'7_0/> [8-TBHX2W+) YT[V.]<&011*7KJ=;];[]I+
M()FM&9=L45/05=<0451]91",PU3]^DQ)D+#,!LHGSU1+S5CY*'?C" H^N<2%
M!MKR;N#EXN:DU!T9;0LSV%2;_9BP'P2O7<W_5IRF+5(,/UK%<+'*@O1;W%+_
MBYZ5*<;;%1R,7EOF5-E?U *F0VBK*,G%S+.F+"B#3!KB0@-[](1H9UUG"^+U
M4/FA?4CNOQZE!P<'\,^BV*&!;/:F,IWM^9KK[N+6\+36*?IQ<!3V3O?-P&Y<
M71(4GHUR5< 5O&S:8<%+%LP4Y*3#9&0 16CLPI)LDE/K:,RO]E/UOWK?_N<4
M)U?^]X.OI)9:XUNQ@[?H,/YD#^-S+C;S859W"E_[URPW,\_,6>+ZSI#L&H!>
M#"   J.:F%30YKQ1APR=N]T=*D3A.DZZ1/'[5I/;JHV("I#MGUNF*I_;0TY6
MULS#2\Y2IV2MC32%V4QP#N@NAL<"JQ'7YMEX(((PC+D!/!J6Y/B!S)\PD"E'
M9DE9JY6>$B4Q.S52 L>2I#T[A1Z_=[9/\5 -5$ED5.&%*JD*047$N"SG% A$
MX),/M6H)8HGZ>T_W$?C2UM2-BHBX#%6+A&L(S4%,V64KP#L8<OC"09O<LZ$\
MLMKD#=Y/JD^]:T3GUM?&=<6BIHMZ.NTJ!FI:F[,4O?9U?A?5YDS8]M[=D7I;
M^:BYETHHEW=. -R_>9DCDRZJFQ<ODU>=\>A!$NSQ)G?P4^/!7IOI_9"\1B.:
MRWS.SY^ER>FC@^27;%R 77RVR(V)D2;'C^;7R<NR!@(KF+U_U\V'-)&?P+D^
M.DJ3/;@KR\?C2Z"I_CF?7..[KYJZFSTPLV NWC.XZV$>'AN5:J8J>0H?39-W
MY@!2URN,"&0.9S:#06(J!Y=Q,:Q9_WD'T7VR')"?Z;S.+Y._9M/9$_KQ_/R=
MD?WD% "F#W8PT0$<GIZ(_,FTZMKV,NNF/Y?F*2BZEOR78CZZ!D7^WNA(_J31
M:"_:_V"8 ;9)F %K%XW; ]:(Y,^3XY].#I)ST"MO.<1G_@?MM)X:S9$OC,.3
MQOZ<PEHTQ3@S@_OA^)$2SAA?UT4^,;LS'W7H5+TEI\6N#G@C>?7SO/ED'"8:
M&]?[NAG'7/+E<YZH*0=;ULSUP@CV,7E9-# 3[QX\>Y#\<&RLQW]!Y^SSNIXE
M[\T5=FT.6F?\R>3HIX/4[,'2Z.;&+,C%_R4__GAR<.AVD)GW!4S^HLP^]N:?
M=@Z\E,S%F; MA+QBD///50G2< #K+"=$G8@+!6DLTF*]UB'7_@,#6Y4"QI79
M0OJYE);1-4!0,:CS>S:4PP.KS]\Q,=,+%?)YZE#LJ-<64=G+4'!TWR,0/&^N
MW1TN4(@AWLD*[!V>$8,;+#81%!<%T> 0BL&Z2\R7L-EI;H1(/3?G3@PN6X44
M0=/10Z\*1S!%D6&I/X)4:$)'S&%H)!E!!9)=@+T!IXWRW,E>HTN2("]E'@8"
M,CKCO$N&RBSZI%QM3@R.3RUG!L-E3H_8W4'V4J?\="1<6F4VJ:W/4;_RF+[$
M([ 9.GB);[%>N"4V<33$)NXV-G$TQ":&B\U<;(?V8CL#OY*LDY?%N!L5T*/V
M5\RI,WK[NICY.&2T1,4&#R@EY#%FW_IY(9P-PBB_.8?26A<RWXAF!Z#'EH@1
MX8D/,=W,*-)BEI5+4S\9KE2ZDZX]8K.=R(C2!)O+0J<2)#-&BN)&C1+R.>8?
M\WQ5Y-N.8V1. *>4JMM&J7&OSMWK-8X00<!/W>CH-;;:=8F([LTX +I:H0P3
M_RN922J9E)/8,NQZ\@03H E2+1B(Y*1'[-3GSYSMD,[5AKXQ"YE"QCPW%[!7
M*N?H>X5.%)(_.T[WI%: T_;[,J^NS)I5^94QAMFUM:L8#S,5U"2<<MPGB7%O
MRBX35U=J_#)A1M>_X?<B/W=KH6AS'IJB_6!)-XEQJ;UUS3!*Y,_&$\R *]26
MD-4)4J)BU=PPC]55=I4SW\QE4V?C!-LEHBQ:#MW2:5&7"RP$A=[M[9S3K\8%
M-DIFBZ%N[7'P]W O40O;/0IE'#+C<<]Q2=.GM]#7 ]H&#[4WD[,HFGEG&YZO
M?^C,-([7FD8BJ!,.!G?F. 'Y<TX;JYX)1^Z"3!0&36#0E ,?! 9YT$\(V\M1
M^(\9I(]@V0!F3W9E"1/'W'%>7CXFXUNR,^R";9O3"1;I1@TR,@<\QD%$.X\[
MIL3B/+C(9W9W\$-WH:!"[=[+<43IS7;J$X,+W;]F!N_Q?D<0W2P<+*.R>C78
MV$=.P9#AQ@6F XX4R\>+CH;Q<PKT>OSO;[&YO9E#.3RRULH_H84]9FN>9Q]O
M\;4!/L./<TT,:7UV19>04P$!M+T5YQ3M=  @*%_96=8O_O[PY.!0OO-/HTZ
M4_JM8N,$I&OI(S%UPB'"$KRA[ 7.*YV4!1T.E*[I2M0V<!0I8 #5/C>>^,Z[
MUBQEP\:^9T,Y/+8;^QGD5^<-X#WMTGW-)&LY@K6TB:%NR.BR*53OC-0S;#A
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M8)$1*%\7E7^#&=S>E_#U]L:^@%ZU2MN-2!++)'7XR<:E;J(RR7R1PUE$?:'
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MPP.2Q?"5;REGD<>+WU[OG]&WFZ_GA;JQDG/\11<78D%"*CG<+Y??+!3.*W?
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M"8NN2T%A48P?3P:D'=OWIL(,&$GU4,EVN*$;U%5**YF@7:P%!;C@RZP;\U+
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MJ IWMP7R5P;C?Y*),Q%]Q/ AXGW# XA_)!.UX&Z<UF>Z;ZJC077>R"-G1/8
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M5EB(!'4K61HEK1MK!3 @C,0.TXXJ(-OT3V02U,N84G,WP6L2D83@![N,UZ$
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M1_Y?Q*F!["Z-FIMHZN4?4$L#!!0    ( $>+!E/B%,("_ H  '^&   5
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M'UI!&:,DG3Y1*&S+)PW"N"F-$-]]2RACE%PS) Z%<]_J480/14*7G^DJ!/K
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M+FAT;5!+ 0(4 Q0    ( $>+!E-(I?..1PX  (9-   )              "
M 6R3  !E>#4M,2YH=&U02P$"% ,4    " !'BP93]$>M28P<  "BO0  "P
M            @ ':H0  9F]R;3@M:RYH=&U02P$"% ,4    " !'BP93RGPV
MDS0#  #X"P  $0              @ &/O@  ;65D<RTR,#(Q,#@P-BYX<V10
M2P$"% ,4    " !'BP93XA3" OP*  !_A@  %0              @ 'RP0
M;65D<RTR,#(Q,#@P-E]L86(N>&UL4$L! A0#%     @ 1XL&4PM#_ I8!P
MW%<  !4              ( !(<T  &UE9',M,C R,3 X,#9?<')E+GAM;%!+
4!08     !@ & &P!  "LU      !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
